



## **EMMANUEL KATSANIS, M.D.**

Professor, Pediatrics, Medicine, Pathology and Immunobiology  
Chief, Tucson-Phoenix Integrated Division of Pediatric Hematology/Oncology  
Director, Adult & Pediatric Hematopoietic Cellular Therapy & Transplant Program  
Associate Chair for Research, Department of Pediatrics  
Louise Thomas Chair in Pediatric Cancer Research  
Peter and Paula Fasseas Chair in Cancer Research  
University of Arizona College of Medicine, Tucson

✉ University of Arizona  
Department of Pediatrics  
1501 N. Campbell Ave.  
PO Box 245073  
Tucson, Arizona 85724

☎ 520-626-7053  
✉ [katsanis@peds.arizona.edu](mailto:katsanis@peds.arizona.edu)  
<http://www.u.arizona.edu/~ekatsani/>  
🐦 [@EmmanuelKatsani](https://twitter.com/EmmanuelKatsani)

## **EDUCATION**

---

Medical School: National University of Athens, Athens, Greece, 1974-1980  
Post-Doctoral Research Associate, McGill University, Montreal, Canada, 1981-82  
Internship: McGill University, Montreal, Canada, 1982-1983  
Residency: Pediatrics, University of Ottawa, Ottawa, Canada, 1983-1987  
Fellowship: Hematology/Oncology, University of Minnesota, Minneapolis, MN, 1987-1990  
Post-Doctoral Research Associate: University of Minnesota, Minneapolis, MN, 1990-1991

## **BOARD CERTIFICATION**

---

Educational Commission for Foreign Medical Graduates, ECFMG, 1980  
Medical Council of Canada Evaluating Examination, MCCEE, 1981  
Licentiate of the Medical Council of Canada, LMCC, 1983  
Federation Licensing Examination, FLEX, 1986  
Royal College of Physicians and Surgeons of Canada, Pediatrics, FRCPC, 1987  
American Board of Pediatrics, Pediatrics, 1987  
American Board of Pediatrics, Pediatric Hematology-Oncology, 1990  
American Board of Pediatrics, Pediatric Hematology-Oncology, re-certification, 1997  
American Board of Pediatrics, Pediatric Hematology-Oncology, re-certification, 2002  
American Board of Pediatrics, Pediatric Hematology-Oncology, re-certification, 2012

## **LICENSURE**

---

Medical Association of Athens, Greece, 1981-83  
College of Physicians and Surgeons of Ontario, #53061, 1983-96  
State of Minnesota Medical License, #31044, 1987-97  
State of Arizona Medical License, #25119, 1997-present



## ACADEMIC APPOINTMENTS (\*denotes active)

---

### University of Minnesota, Medical School, Minneapolis, MN

Instructor of Pediatrics, 1991-1993

Assistant Professor of Pediatrics, 1993-1997 (Tenure track)

### University of Arizona, College of Medicine, Tucson, AZ

Assistant Professor of Pediatrics, 1997-1998 (Tenure track)

Associate Professor of Pediatrics, 1998-2004 (Tenured)

Associate Professor of Pathology, 1999-2004

\*Professor of Pediatrics, 2004-present (Tenured)

\*Professor of Pathology, 2004-present

\*Professor of Immunobiology, 2007-present

\*Professor of Medicine, 2012-present

Interim Chief, Division of Pediatric Hematology/Oncology, 2004-2005

Director, M.D.-Ph.D. Program, 2010-2014

Associate Director Translational Research, UA Cancer Center, 2014-2015

\*Chief, Division of Pediatric Hematology/Oncology, 2005-present

\*Associate Chair for Research, Department of Pediatrics, 2011-present

\*Director, Hematopoietic Cellular Therapy and Transplant Program, UA Cancer Center, 2012-present

## HOSPITAL DIRECTORSHIPS (\*denotes active)

---

\*Medical Director, HCTT Laboratory, Banner University Medical Center, 1999-present

\*Medical Director, Pediatric Oncology, Banner University Medical Center, 2008-present

\*Medical Director, Pediatric BMT, Banner University Medical Center, 2010-present

\*Division Chief, Banner Children's Hematology/Oncology, Tucson & Phoenix, 2018-present

## HONORS & AWARDS (\*denotes active)

---

Gordon E. Richard Award, Canadian Cancer Society Fellowship, 1986-1987

Award for Best Research Presentation by a Pediatric Resident, University of Ottawa, 1987

Wyeth Award for Excellence Achieved in Research, University of Ottawa, 1987

Outstanding Pediatric Fellow Award, University of Minnesota, 1988

Variety Club Fellowship, 1989-1990

Fellowship Award, Medical Research Council of Canada, 1989-1991

First Place Award, University of Minnesota Pediatric Fellows' Research Symposium, 1990

Irvine McQuarrie Research Scholar Award, 1992-1994

Young Investigator Award, American Society of Pediatric Hematology/Oncology, 1992

Clinical Oncology Career Development Award, American Cancer Society, 1993-1996

Leading Edge Researcher Award, University of Arizona, 2009

\*Louise Thomas Endowed Chair in Pediatric Cancer Research, 2005-present

\*Peter and Paula Fasseas Endowed Chair in Cancer Research, 2012-present



## SCIENTIFIC ACTIVITIES

---

### National Institutes of Health Study Sections

NIH/NCI Program Project Site Visit Committee, Children's Hospital Los Angeles, USC, 1998  
 NIH/NCI Scientific Review Committee D, Clinical Research Studies, 1999  
 NIH/NCI Program Project Site Visit Committee, Rush University Medical Center, 2003  
 NIH/NCI Special Emphasis Panel/Approaches in Cancer Therapeutics, 2005  
 NIH/NCI Cancer Immunopathology and Immunotherapy Study Section, Feb-2006  
 NIH/NCI Special Emphasis Panel/Cancer Therapy (Onc-B), 2006  
 NIH/NCI Cancer Immunopathology and Immunotherapy Study Section, Jan-2008  
 NIH/NCI Cancer Immunopathology and Immunotherapy Study Section, Oct-2008  
 NIH/NCI Clinical Oncology Study Section, Jan-2009  
 NIH/NCI Clinical Oncology Study Section, May-2009  
 NIH/NCI RFA OD-09-003 Challenge Grants Panel 10, June-2009  
 NIH/NCI Cancer Immunopathology and Immunotherapy Study Section, Sep-2009  
 NIH/NCI Pediatric Research-LRP OD09-109 Pediatric L40 A2, May-2010  
 NIH/NCI ZRG1 OTC-Y (02)-Cancer Therapeutics, Dec-2010  
 NIH/NCI Intramural Program Site Visit Committee, Pediatric Oncology Branch, May 2011  
 NIH/NCI Pediatric Research-LRP 2012/08 ZCA1 PCRB-A (A2) B, May-2012  
 NIH/NCI Pediatric Research-LRP 2014/08 ZCA1 PCRB-A (A2) S, May-2014  
 NIH/NCI Clinical Oncology Study Section, **Chartered Member, 2010-2014**  
 NIH/NCI Pediatric Research-LRP 2015/08 ZCA1 PCRB-A (A2) S, May 2015  
 NIH/NCATS Support for Conferences and Scientific Meeting 2015/01 ZTR1 CG-4 (01) 1, Oct 2015  
 NIH/NCI Special Emphasis Panel/Clinical Translational R21: 2017/01 ZCA1 RPRB-Z (J2) S, Oct 2016  
 NIH/NCI Clinical Oncology Study Section, Feb-2017  
 NIH/NCATS CTSA Collaborative Innovation Award Review, 2018/05 ZTR1 CI-4 (01) 1, Feb 2018

### Other Grant Review Panels (\*denotes international)

American Cancer Society, Scientific Advisory Committee on Immunology, 1993  
 \*Manitoba Health Research Council, 1995  
 \*Children's Hospital of Winnipeg Research Foundation, 1995  
 \*Children's Hospital of Eastern Ontario Research Institute, 1996  
 \*University of Manitoba Health Sciences Centre Foundation, 1995, 1996  
 American Cancer Society, Peer Review Committee on Cancer Immunology, 1997  
 \*Italian Association for Cancer Research, 2004  
 Miami Children's Hospital Research Institute, 2004  
 Dept. of Defense (DOD) Chronic Myelogenous Leukemia Research Program (CMLRP), 2004  
 \*National Medical Research Council of Singapore, 2004  
 \*Italian Association for Cancer Research, 2009  
 \*Italian Association for Cancer Research, 2010  
 \*Greek Ministry for Education (Grant proposal review), 2011  
 American Cancer Society, IRG, 2011  
 \*Italian Association for Cancer Research, 2011  
 \*Cancer Research Wales, 2011  
 \*Michael Smith Foundation for Health Research, British Columbia, Canada, 2012  
 St. Baldrick's Foundation, 2012  
 \*Italian Association for Cancer Research, 2012  
 UA Cancer Center, Basic/clinical partnerships to promote translational research, 2012  
 \*Italian Association for Cancer Research, 2013



St. Baldrick's Foundation, 2013  
\*Netherlands Organisation for Scientific Research, 2013  
St. Baldrick's Foundation, 2014  
\*Italian Association for Cancer Research, 2014  
Medical Research Council, United Kingdom, 2014  
St. Baldrick's Foundation, 2015  
\*Italian Association for Cancer Research, 2015  
American Cancer Society, IRG, 2015  
St. Baldrick's Foundation, 2016  
\*Italian Association for Cancer Research, 2016  
St. Baldrick's Foundation, 2017  
\*Italian Association for Cancer Research, 2017  
\*National Children's Research Centre (NCRC), Republic of Ireland, 2017  
\*Stavros Niarchos Foundation, Research Training Program in Clinical & Experimental Medicine, 2017  
Children's Cancer Research Fund, 2018  
St. Baldrick's Foundation, 2018  
\*Stand up to Cancer (Kom op tegen Kanker), Biomedical Research Grants, Belgium, 2018  
\*Italian Association for Cancer Research, 2018  
St. Baldrick's Foundation, 2019  
St. Baldrick's Foundation, 2020  
\*Italian Association for Cancer Research, 2020  
\*Ludwig Boltzmann Gesellschaft Institution, Austria, 2020

#### Scientific Committees/Boards

Session Chairperson, International Society for Experimental Hematology Meeting, 1994  
Chairman, Scientific Advisory Board, Immunovative Therapies, Ltd., Sep 2012- Jan 2013

#### Professional Societies (\*denotes active)

Fellow of the Royal College of Physicians and Surgeons of Canada, 1987-2009  
European Society for Cancer Immunology and Immunotherapy, 2006-2014  
American Association of Immunologists, 1995-2017  
\*American Association for Cancer Research, 1989-present  
\*Society for Immunotherapy of Cancer, 1992-present  
\*American Society of Hematology, 1997-present  
\*Children's Oncology Group, 2000-present  
\*American Society of Pediatric Hematology/Oncology, 2008-present  
\*American Society for Transplantation and Cell Therapy, 2010-present  
\*Pediatric Blood and Marrow Transplant Consortium, 2010-present  
\*AACR, Cancer Immunology Working Group, 2011-present  
\*AACR, Pediatric Cancer Working Group, 2011-present  
\*European Academy for Tumor Immunology, 2016-present



### **Journal Editorial Boards**

HAEMA, 2005-2010  
Cancer Immunology Immunotherapy, 2007-13  
International Journal of Oncology, 2008-14  
International Journal of Pediatrics, 2009-14  
American Journal of Blood Research, Senior Editorial Board, 2011-15  
Frontiers in Pediatrics, Guest Associate Editor, 2019-  
Frontiers in Oncology, Guest Associate Editor, 2020  
Cancers, 2021-  
Frontiers in Immunology, Associate Editor, 2021-

### **Journal Reviewer**

Biology of Blood and Marrow Transplantation  
BLOOD  
Biomedical Research International  
BMC Cancer  
BMC Pediatrics  
BMJ Case Reports  
British Journal of Haematology  
Cancer Gene Therapy  
Cancer Research  
Cancers  
Cells  
Cellular Immunology  
Critical Reviews in Oncology/Hematology  
Cytotherapy  
Hospital Physician  
EBiomedicine  
European Journal of Immunology  
Expert Opinion on Biological Therapy  
Expert Review of Vaccines  
Frontiers in Immunology  
Immunobiology  
Immunologic Research  
Immunological Investigations  
Immunotherapy  
International Immunopharmacology  
International Journal of Cancer  
Journal of Cellular Biochemistry  
Journal of Clinical Medicine  
Journal of Hematology and Oncology  
Journal of Immunology  
Journal of Immunotherapy  
Journal of Leukocyte Biology  
Journal of Pediatric Infectious Diseases  
Journal of Pediatrics  
Journal of Pharmacology and Experimental Therapeutics  
Journal of the National Cancer Institute  
Leukemia  
Nature Medicine



Neuro-Oncology  
 Oncogene  
 The Oncologist  
 Oncology Letters  
 Oncotarget  
 Pediatric Blood and Cancer  
 Pediatric Transplantation  
 PLOS ONE  
 Transplantation  
 Tumor Biology

## **COMMITTEE & ADMINISTRATIVE ACTIVITIES** (\*denotes active)

---

### **Faculty Member**

University of Minnesota Cancer Center, 1994-1997  
 University of Minnesota Center for Immunology, 1995-1997  
 \*University of Arizona Cancer Center, 1997-present  
 \*University of Arizona Steele Children's Research Center, 1997-present  
 \*University of Arizona Interdisciplinary Graduate Program in Cancer Biology, 1998-present  
 \*University of Arizona Graduate Program in Immunobiology, 1999-present  
 \*University of Arizona BIO5 Institute, 2005-present

### **University**

Faculty Council, University of Ottawa, 1983-84  
 Frontiers in Immunobiology & Immunopathogenesis Symposium Committee, UA, 2005-2008  
 Chairman, Committee for Review of the Head of the Dept. of Pediatrics, UA, 2006-2007  
 Promotion and Tenure Committee, University of Arizona, College of Medicine, 2008-2010  
 Founders Day Selection Committee, University of Arizona, College of Medicine, 2009  
 Endowed Chair Committee, University of Arizona, College of Medicine, 2009-11  
 Tactical Team for UA Healthcare Integration, University of Arizona, College of Medicine, 2010-2012  
 M.D.-Ph.D. Committee, University of Arizona, College of Medicine, 2010-2014  
 Dean's Graduate Program Advisory Committee, University of Arizona, 2011-2014  
 Search Committee, Director of the University of Arizona Cancer Center, 2012-2013  
 Institutional Setting Committee, Self-Study Task Force, UA College of Medicine, 2012-2014  
 University of Arizona Health Sciences Health Disparities Advisory Council, 2013-2014  
 UA Vitae College of Medicine Faculty Advisory Committee, 2015  
 Search Committee for BIO5 Institute Director, University of Arizona, 2017  
 Dean's Research Council, University of Arizona, College of Medicine, 2013-18  
 Resident Research Council, University of Arizona, College of Medicine, 2011-18  
 College of Medicine Faculty Fellow Mentoring Program, University of Arizona, 2015-18  
 \*Dean's Faculty Advisory Committee, University of Arizona, College of Medicine, 2020-23

### **Centers**

Immunobiology Core Committee, University of Arizona Cancer Center (UACC), 1999-2004  
 Stem Cell Transplantation M&M Committee, University of Arizona Cancer Center, 2004-2005  
 Experimental Mouse Shared Service Committee, University of Arizona Cancer Center, 2004-2005  
 Director's Committee, University of Arizona Cancer Center, 2006-2013



Clinical Operations Executive Committee, University of Arizona Cancer Center 2008-2013  
Joint Oversight Committee, University of Arizona Cancer Center, 2013-2015  
Chair, Cancer Immunotherapy and Transplantation Conference, UACC 2013-17  
Chair, Tumor Immunology Search Committee, University of Arizona Cancer Center, 2016-17  
Executive Council, University of Arizona Cancer Center, 2014-19  
Chair, Membership Committee, University of Arizona Cancer Center, 2015-2020  
Co-leader, Precision Immunotherapy Focus Group, UACC, 2019  
\*Gastrointestinal Malignancies Translational Cancer Biologist Search Committee, UACC 2021

### Departments

Pediatric Bone Marrow Transplantation Committee, U of Minnesota, 1991-1997  
Faculty Development Committee, Dept. of Pediatrics, U Arizona, 1998-2002  
Computer Committee, Dept. of Pediatrics, U Arizona, 1998-2002  
Director of Transfusion Medicine Search Committee, Dept. of Pathology, U Arizona, 2001  
Space Committee, Dept. of Pediatrics, U Arizona, 2008-2010  
Faculty Recruitment Search Committee, Dept. of Immunobiology, 2008-2010  
Academic Program Review, Dept. of Immunobiology, U Arizona, 2011  
Academic Program Review, Dept. of Radiation Oncology, U Arizona, 2015  
Promotion and Evaluation Committee, Dept. of Immunobiology, 2007-2016  
\*Clinical Steering Committee, Dept. of Pediatrics, U Arizona, 2004-present  
\*Executive Committee, Dept. of Pediatrics, U Arizona, 2011-present  
\*Mentoring Committee, Dept. of Pediatrics, U Arizona, 2012-present  
\*Chair, Promotion and Tenure Committee, Dept. of Pediatrics, 2016-present

### Graduate Programs

Interviewer, Cancer Biology Graduate Interdisciplinary Program (GIDP), U Arizona, 2005-2007  
Admissions Committee, Dept. of Immunobiology Graduate Program, U Arizona, 2005-2008  
Executive Committee, Immunobiology Graduate Program, U Arizona, 2007-2011  
Admissions Committee, Cancer Biology GIDP, UA, 2007-2011  
NIH T32 Training Grant Selection Committee, Cancer Biology GIDP, U Arizona, 2010-2011  
Curriculum Committee, Cancer Biology GIDP, U Arizona, 2010-13  
Academic Program Review, Cancer Biology GIDP, U Arizona, 2011  
Executive Committee, Cancer Biology GIDP, U Arizona, 2007-18  
Academic Program Review, Cancer Biology GIDP, U Arizona, 2018

### Hospital

Oncology subcommittee pharmacy and therapeutics committee, UA Medical Center, 2011-2014  
\*Executive Committee for the Cancer Service Line, Banner University Medical Center, 2016-present

### Community

Leukemia and Lymphoma Society, Tucson Chapter Leadership Committee Member, 2016-17  
\*Ronald McDonald House Charities, Southern Arizona, Member of the Board of Directors, 2021-



## **OTHER SERVICE**

---

Interviewer, College of Medicine Admissions, University of Arizona, 1999-2008  
Interviewer, Department of Surgery, Faculty Recruitment, 2007-2008  
Evaluator, Faculty Appointment, Chinese University of Hong Kong, 2016  
Interviewer, Department of Pediatrics Residency Program, University of Arizona, 1998-2019

## **CLINICAL ACTIVITIES** (\*denotes active)

---

Pediatric Blood and Marrow Transplantation, University of Minnesota, 1991-1997  
Pediatric Hematology-Oncology and BMT, University of Arizona, 1997- 2010  
\*Pediatric Hematopoietic Cellular Therapy & Transplant, Banner University Medical Center 2010-





## BIBLIOGRAPHY: Stats

---

- **Peer-Reviewed Publications Impact Factor**  
 Total (1983-present); n=127, avg IF 7.41  
 University of Arizona (1998-present); n=90 avg IF 7.19  
 University of Arizona (first or senior author, excluding clinical publications); n=44 avg IF 8.86
- **My NCBI**
- **Google Scholar-** (h-index 46, i-10-index 95)
- **Scopus-** (h-index 38, i-10-index 85), Author ID: 7006066391
- **Orcid ID-** 0000-0003-1466-6965

## BIBLIOGRAPHY: Peer-Reviewed Journal Publications

---

1. Tolis G, Montes J, Katsanis E, Bertrand G. Aspects of prolactin pathophysiology in relation to prolactin secreting adenomas. *Period Biol* **1983** 85(suppl 1): 29-36.

### Publications #2-7 during residency, University of Ottawa, Canada

2. Katsanis E, McLaine PN. Wegener granulomatosis. *J Pediatr* **1986** May;108(5 Pt 1):792-3. PMID: 3701531
3. Katsanis E, Hsu E, Luke KH, McKee JA. Systemic lupus erythematosus and sickle hemoglobinopathies: a report of two cases and review of the literature. *Am J Hematol* **1987** Jun;25(2):211-4. PMID: 3605068
4. Katsanis E, Luke KH, Hsu E, Yates JR. Hemoglobin E: a common hemoglobinopathy among children of Southeast Asian origin. *Can Med Assoc J* **1987** Jul 1;137(1):39-42. PMID: 3594333  
 PMCID: [PMC1492394](#)
5. Katsanis E, Luke KH, Hsu E, Carpenter BF, Mantynen PR. Neutrophilic eccrine hidradenitis in acute myelomonocytic leukemia. *Am J Pediatr Hematol Oncol* **1987** Fall;9(3):204-8. PMID: 3479026
6. Katsanis E, Luke KH, Hsu E, Li M, Lillicrap D. Prevalence and significance of mild bleeding disorders in children with recurrent epistaxis. *J Pediatr* **1988** Jul;113(1 Pt 1):73-6. PMID: 3385532 (89 citations)
7. Kempe A, Hall CB, MacDonald NE, Foye HR, Woodin KA, Cohen HJ, Lewis ED, Gullace M, Gala CL, Dulberg CS, Katsanis E. Influenza in children with cancer. *J Pediatr* **1989** 115: 33-39. PMID: 2738793 (129 citations)

### Publications #8-14 during fellowship, University of Minnesota

8. Katsanis E, Ramsay NK. Treatment of acquired severe aplastic anemia. *Am J Pediatr Hematol Oncol* **1989** Fall;11(3):360-7. PMID: 2675662



9. Anderson PM, Katsanis E, Leonard AS, Schow D, Loeffler CM, Goldstein MB, Ochoa AC. Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases. **Cancer Res** **1990** Mar 15;50(6):1853-6. PMID: 2306737 (89 citations)
10. Katsanis E, Shapiro RS, Robison LL, Haake RJ, Kim T, Pescovitz OH, Ramsay NK. Thyroid dysfunction following bone marrow transplantation: long-term follow-up of 80 pediatric patients. **Bone Marrow Transplant** **1990** May;5(5):335-40. PMID: 2350628 (83 citations)
11. Katsanis E, Bausero MA, Ochoa AC, Loeffler CM, Blazar BR, Leonard AS, Anderson PM. Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytotoxicity. **Cancer Immunol Immunother** **1991** 34(2):74-8. PMID: 1760819
12. Loeffler CM, Platt JL, Anderson PM, Katsanis E, Ochoa JB, Urba WJ, Longo DL, Leonard AS, Ochoa AC. Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis. **Cancer Res** **1991** Apr 15;51(8):2127-32. PMID: 1826232 (74 citations)
13. Katsanis E, Anderson PM, Filipovich AH, Hasz DE, Rich ML, Loeffler CM, Ochoa AC, Weisdorf DJ. Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation. **Blood** **1991** Sep 1;78(5):1286-91. PMID: 1831682
14. Sencer SF, Rich ML, Katsanis E, Ochoa AC, Anderson PM. Anti-tumor vaccine adjuvant effects of IL-2 liposomes in mice immunized against MCA-102 sarcoma. **Eur Cytokine Netw** **1991** Nov-Dec;2(5):311-8. PMID: 1804322

#### Publications #15-36 & 38 as Assistant Professor, University of Minnesota

15. Anderson PM, Katsanis E, Sencer SF, Hasz D, Ochoa AC, Bostrom B. Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. **J Immunother** **1992** Jul;12(1):19-31. PMID: 1637781 (71 citations)
16. Katsanis E, Orchard PJ, Bausero MA, Gorden KB, McIvor RS, Blazar BR. Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. **J Immunother** **1994** Feb;15(2):81-90. PMID: 8136949
17. Katsanis E, Bausero MA, Xu H, Orchard PJ, Xu Z, McIvor RS, Brian AA, Blazar BR. Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing. **Cancer Immunol Immunother** **1994** Feb;38(2):135-41. PMID: 7905790
18. Katsanis E, Blazar BR, Bausero MA, Gunther R, Anderson PM. Retroperitoneal inoculation of murine neuroblastoma results in a reliable model for evaluation of the antitumor immune response. **J Pediatr Surg** **1994** Apr;29(4):538-42. PMID: 8014811
19. Katsanis E, Weisdorf DJ, Xu Z, Dancisak BB, Halet ML, Blazar BR. Infusions of interleukin-1 alpha after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytotoxic activity. **J Clin Immunol** **1994** May;14(3):205-11. PMID: 7929695



20. Weisdorf D, Katsanis E, Verfaillie C, Ramsay NK, Haake R, Garrison L, Blazar BR. Interleukin-1 alpha administered after autologous transplantation: a phase I/II clinical trial. **Blood** **1994** Sep 15;84(6):2044-9. PMID: 7915916
21. Katsanis E, Xu Z, Anderson PM, Dancisak BB, Bausero MA, Weisdorf DJ, Blazar BR, Ochoa AC. Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in in vivo expansion of effector cells with potent anti-lymphoma activity. **Bone Marrow Transplant** **1994** Oct;14(4):563-72. PMID: 7858530
22. Katsanis E, Xu Z, Bausero MA, Dancisak BB, Gorden KB, Davis G, Gray GS, Orchard PJ, Blazar BR. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. **Cancer Gene Ther** **1995** Mar;2(1):39-46. PMID: 7542553
23. Bausero MA, Panoskaltis-Mortari A, Blazar BR, Katsanis E. Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-gamma. **J Immunother** **1996** Mar;19(2):113-24. PMID: 8732694
24. Katsanis E, Bausero MA, Panoskaltis-Mortari A, Dancisak BB, Xu Z, Orchard PJ, Davis CG, Blazar BR. Irradiation of singly and doubly transduced murine neuroblastoma cells expressing B7-1 and producing interferon-gamma reduces their capacity to induce systemic immunity. **Cancer Gene Ther** **1996** Mar-Apr;3(2):75-82. PMID: 8729905
25. Orchard PJ, Katsanis E, Boyer M, May C, McIvor RS, Blazar BR. Interleukin-2 secretion by transduced and unselected BDL-2 lymphoma results in increased survival in mice with previously established disseminated disease. **Cancer Biother Radiopharm** **1996** Apr;11(2):155-64. PMID: 10851532
26. Katsanis E, Xu Z, Panoskaltis-Mortari A, Weisdorf DJ, Widmer MB, Blazar BR. IL-15 administration following syngeneic bone marrow transplantation prolongs survival of lymphoma bearing mice. **Transplantation** **1996** Sep 27;62(6):872-5. PMID: 8824494
27. Saltzman DA, Katsanis E, Heise CP, Hasz DE, Vigdorovich V, Kelly SM, Curtiss R 3rd, Leonard AS, Anderson PM. Antitumor mechanisms of attenuated Salmonella typhimurium containing the gene for human interleukin-2: a novel antitumor agent? **J Pediatr Surg** **1997** Feb;32(2):301-6. PMID: 9044141 (52 citations)
28. Davies SM, Wagner JE, Shu XO, Blazar BR, Katsanis E, Orchard PJ, Kersey JH, Dusenbery KE, Weisdorf DJ, McGlave PB, Ramsay NK. Unrelated donor bone marrow transplantation for children with acute leukemia. **J Clin Oncol** **1997** Feb;15(2):557-65. PMID: 9053477 (113 citations)
29. Xu Z, Katsanis E. Improved immunostimulatory function of bone marrow derived macrophages transduced with the granulocyte-macrophage colony stimulating factor gene. **Cancer Biother Radiopharm** **1997** Feb; 12(1):27-36. PMID: 10851444
30. Saltzman DA, Katsanis E, Heise CP, Hasz DE, Kelly SM, Curtiss R 3rd, Leonard AS, Anderson PM. Patterns of hepatic and splenic colonization by an attenuated strain of Salmonella typhimurium containing the gene for human interleukin-2: a novel anti-tumor agent. **Cancer Biother Radiopharm** **1997** Feb;12(1):37-45. PMID: 10851445



31. Davies SM, Wagner JE, Defor T, Blazar BR, Katsanis E, Kersey JH, Orchard PJ, McGlave PB, Weisdorf DJ, Ramsay NK. Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia. **Br J Haematol** **1997** Mar;96(4):749-56. PMID: 9074418 (75 citations)
32. Khanna C, Anderson PM, Hasz DE, Katsanis E, Neville M, Klausner JS. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. **Cancer** **1997** Apr 1;79(7):1409-21. PMID: 9083164 (140 citations)
33. Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, Katsanis E, Verfaillie C, Lebkowski J, Radford J Jr, Burns LJ. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. **Biol Blood Marrow Transplant** **1997** Apr;3(1):34-44. PMID: 9209739 (105 citations)
34. Boyer MW, Vallera DA, Taylor PA, Gray GS, Katsanis E, Gorden K, Orchard PJ, Blazar BR. The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties. **Blood** **1997** May 1;89(9):3477-85. PMID: 9129056 (61 citations)
35. Khanna C, Waldrep JC, Anderson PM, Weichelbaum RW, Hasz DE, Katsanis E, Klausner JS. Nebulized interleukin 2 liposomes: aerosol characteristics and biodistribution. **J Pharm Pharmacol** **1997** Oct;49(10):960-71. PMID: 9364403
36. Katsanis E, Weisdorf DJ, Miller JS. Activated peripheral blood mononuclear cells from patients receiving subcutaneous interleukin-2 following autologous stem cell transplantation prolong survival of SCID mice bearing human lymphoma. **Bone Marrow Transplant** **1998** Jul;22(2):185-91. PMID: 9707028

#### Publications #37 and from 39 to 50 as Associate Professor, University of Arizona

37. Smith DF, Whitesell L, Katsanis E. Molecular chaperones: biology and prospects for pharmacological intervention. **Pharmacol Rev** **1998** Dec;50(4):493-514. PMID: 9860803 (287 citations)
38. Perentesis J, Katsanis E, DeFor T, Neglia J, Ramsay N. Autologous stem cell transplantation for high-risk pediatric solid tumors. **Bone Marrow Transplant** **1999** Sep;24(6):609-15. PMID: 10490725 (51 citations)
39. Graner M, Raymond A, Romney D, He L, Whitesell L, Katsanis E. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. **Clin Cancer Res** **2000** Mar;6(3):909-15. PMID: 10741715 (99 citations)
40. Yorgin PD, Hartson SD, Fella AM, Scroggins BT, Huang W, Katsanis E, Couchman JM, Matts RL, Whitesell L. Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases. **J Immunol** **2000** Mar 15;164(6):2915-23. PMID: 10706677 (63 citations)
41. Graner M, Raymond A, Akporiaye E, Katsanis E. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. **Cancer Immunol Immunother** **2000** Nov;49(9):476-84. PMID: 11092614 (69 citations)
42. McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, Dumont N, Besselsen D, Seftor E, Hendrix MJ, Katsanis E, Akporiaye ET. Invasion and metastasis of a mammary tumor



- involves TGF-beta signaling. ***Int J Cancer* 2001** Jan 1;91(1):76-82. PMID: 11149423 (198 citations)
43. He L, Feng H, Raymond A, Kreeger M, Zeng Y, Graner M, Whitesell L, Katsanis E. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. ***Cancer Immunol Immunother* 2001** Mar;50(1):31-40. PMID: 11315508 (70 citations)
  44. Feng H, Zeng Y, Whitesell L, Katsanis E. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. ***Blood* 2001** Jun 1;97(11):3505-12. PMID: 11369644 (198 citations)
  45. Feng H, Zeng Y, Graner MW, Katsanis E. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. ***Blood* 2002** Dec 1;100(12):4108-15. PMID: 12393401 (200 citations)
  46. Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. ***Blood* 2003** Jan 1;101(1):245-52. PMID: 12393411 (132 citations)
  47. Graner MW, Zeng Y, Feng H, Katsanis E. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. ***Cancer Immunol Immunother* 2003** Apr;52(4):226-34. PMID: 12669247 (104 citations)
  48. Zeng Y, Feng H, Graner MW, Katsanis E. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. ***Blood* 2003** Jun 1;101(11):4485-91 PMID: 12576309 (113 citations)
  49. Feng H, Zeng Y, Graner MW, Whitesell L, Katsanis E. Evidence for a Novel, Caspase-8-Independent, Fas Death Domain-Mediated Apoptotic Pathway. ***J Biomed Biotechnol (Biomed Res Int)* 2004** 2004(1):41-51. PMID:15123887, PMCID: [PMC545657](https://pubmed.ncbi.nlm.nih.gov/15123887/)
  50. Zeng Y, Graner MW, Feng H, Li G, Katsanis E. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. ***Int J Cancer* 2004** Jun 10;110(2):251-9. PMID: 15069690

#### **Publications #51-130 as Professor, University of Arizona**

51. Graner MW, Likhacheva A, Davis J, Raymond A, Brandenberger J, Romanoski A, Thompson S, Akporiaye E, Katsanis E. Cargo from tumor-expressed albumin inhibits T-cell activation and responses. ***Cancer Res* 2004** Nov 1;64(21):8085-92. PMID: 15520220
52. Zeng Y, Graner MW, Thompson S, Marron M, Katsanis E. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells. ***Blood* 2005** Mar 1;105(5):2016-22. PMID:15374884 PMCID: [PMC1227556](https://pubmed.ncbi.nlm.nih.gov/15374884/)
53. Ramanathapuram LV, Hahn T, Graner MW, Katsanis E, Akporiaye ET. Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines. ***Cancer Immunol Immunother* 2006** Feb;55(2):166-77. PMID: 16041582
54. Zeng Y, Graner MW, Katsanis E. Chaperone-rich cell lysates, immune activation and tumor vaccination. ***Cancer Immunol Immunother* 2006** Mar;55(3):329-38. PMID: 15887013 (54 citations)



55. Chen X, Zeng Y, Li G, Larmonier N, Graner MW, Katsanis E. Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity. ***Biol Blood Marrow Transplant* 2006** Mar;12(3):275-83. PMID: 16503496
56. Larmonier N, Mérino D, Nicolas A, Cathelin D, Besson A, Bateman A, Solary E, Martin F, Katsanis E, Bonnotte B. Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading. ***Apoptosis* 2006** Sep;11(9):1513-24. PMID: 16738802 (57 citations)
57. Zeng Y, Chen X, Larmonier N, Larmonier C, Li G, Sepassi M, Marron M, Andreansky S, Katsanis E. Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination. ***Int J Cancer* 2006** Dec 1;119(11):2624-31. PMID: 16989012
58. Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, Thompson S, Chen X, Andreansky S, Katsanis E. Tumor-derived CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. ***Cancer Immunol Immunother* 2007** Jan;56(1):48-59. PMID: 16612596 (286 citations)
59. Chen X, Zhou B, Li M, Deng Q, Wu X, Le X, Wu C, Larmonier N, Zhang W, Zhang H, Wang H, Katsanis E. CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. ***Clin Immunol* 2007** Apr;123(1):50-9. PMID: 17234458 (354 citations)
60. Li G, Zeng Y, Chen X, Larmonier N, Sepassi M, Graner MW, Andreansky S, Brewer MA, Katsanis E. Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. ***Clin Exp Immunol* 2007** Apr;148(1):136-45. PMID: 17349014 PMCID: [PMC1868858](#)
61. Kislin KL, Marron MT, Li G, Graner MW, Katsanis E. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia. ***FASEB J* 2007** Jul;21(9):2173-84. PMID: 17327358
62. Larmonier N, Cathelin D, Larmonier C, Nicolas A, Merino D, Janikashvili N, Audia S, Bateman A, Thompson J, Kottke T, Hartung T, Katsanis E, Vile R, Bonnotte B. The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. ***Exp Cell Res* 2007** Jul 1;313(11):2345-55. PMID: 17466973
63. Li G, Andreansky S, Helguera G, Sepassi M, Janikashvili N, Cantrell J, Lacasse CL, Larmonier N, Penichet ML, Katsanis E. A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. ***Mol Cancer Ther* 2008** Mar;7(3):721-9. PMID:18347157,
64. Larmonier N, Cantrell J, Lacasse C, Li G, Janikashvili N, Situ E, Sepassi M, Andreansky S, Katsanis E. Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression. ***J Leukoc Biol* 2008** Apr;83(4):1049-59. PMID: 18174364
65. Larmonier N, Janikashvili N, LaCasse C, Larmonier C, Cantrell J, Situ E, Li G, Bonnotte B, Katsanis E. Imatinib mesylate suppresses CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cell activity and enhances active immunotherapy against BCR-ABL negative tumors. ***J Immunol* 2008** Nov 181:6955-63. PMID: 18981115, PMCID: [PMC2579962](#) (163 citations)
66. Bleifuss E, Bendz H, Sirch B, Thompson S, Brandl A, Milani V, Graner MW, Drexler I, Kuppner M, Katsanis E, Noessner E, Issels RD. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens. ***Int J Hyperther* 2008** Dec;24(8):623-37. PMID: 18608582



67. Janikashvili N, Larmonier N, [Katsanis E](#). Personalized dendritic cell-based tumor immunotherapy. ***Immunother* 2010** Jan 2(1):57-68. PMID: 20161666 PMCID: [PMC2819192](#) (69 citations)
68. Larmonier N, Fraszczak J, Lakomy D, Bonnotte B, [Katsanis E](#). Killer dendritic cells and their potential for cancer immunotherapy. ***Cancer Immunol Immunother* 2010** Jan 59(1):1-11. PMID: 19618185 (70 citations)
69. Fraszczak J, Trad M, Janikashvili N, Cathelin D, Lakomy D, Granci V, Morizot A, Audia S, Micheau O, Lagrost L, [Katsanis E](#), Solary E, Larmonier N, Bonnotte B. Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells. ***J Immunol* 2010** Feb 15; 184(4):1876-84. PMID: 20089706 (60 citations)
70. Cantrell J, Larmonier C, Janikashvili N, Bustamante S, Fraszczak J, Herrell A, Lundeen T, LaCasse C, Situ E, Larmonier N, [Katsanis E](#). Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells. ***Immunobiology* 2010** July 215(7):535-544. PMID:19880213, PMCID: [PMC2881173](#)
71. Janikashvili N, LaCasse C, Larmonier C, Trad M, Herrell A, Bustamante S, Har-Noy M, Larmonier N, [Katsanis E](#). Allogeneic effector/memory Th-1 cells impair FoxP3<sup>+</sup> regulatory T cells and synergize with chaperone-rich cell lysate vaccine to treat leukemia. ***Blood* 2011** Feb 3;117(5):1555-64. PMID:21123824, PMCID: [PMC3056591](#)
72. Janikashvili N, Bonnotte B, [Katsanis E](#), Larmonier N. The dendritic cell-regulatory T lymphocyte cross-talk contributes to tumor-induced tolerance. ***Clin Dev Immunol (J Immunol Res)* 2011** 2011:430394. PMID:22110524, PMCID: [PMC3216392](#) (91 citations)
73. Lakomy D, Janikashvili N, Fraszczak J, Trad M, Audia S, Samson M, Ciudad M, Vinit J, Vergely C, Caillot D, Foucher P, Lagrost L, Chouaib S, [Katsanis E](#), Larmonier N, Bonnotte B. Cytotoxic dendritic cells generated from cancer patients. ***J Immunol* 2011** Sep 1;187(5):2775-82. PMID:21804019, PMCID: [PMC3159799](#)
74. Audia S, Samson M, Guy J, Janikashvili N, Fraszczak J, Trad M, Ciudad M, Leguy V, Berthier S, Petrella T, Aho-Glele S, Martin L, Maynadie M, Lorcerie B, Rat P, Cheynel N, [Katsanis E](#), Larmonier N, Bonnotte B. Immunological effects of rituximab on the human spleen in immune thrombocytopenia. ***Blood* 2011** Oct 20;118(16):4394-400. PMID:21876120, PMCID: [PMC3204911](#) (116 citations)
75. LaCasse CJ, Janikashvili N, Larmonier C, Alizadeh D, Hanke NT, Kartchner J, Situ E, Centuori S, Bonnotte B, [Katsanis E](#)\*, Larmonier N\*. T helper-1 lymphocytes induce the tumor killing function of dendritic cells by an interferon- $\gamma$ -dependent mechanism. ***J Immunol* 2011** Dec 15;187(12):6310-7. PMID: 22075702, PMCID: [PMC3297475](#)
76. Larmonier N, Bonnotte B, [Katsanis E](#). Cytotoxic and antigen presenting functions of T helper-1-activated dendritic cells. ***Oncoimmunol* 2012** Jul 1;1(4):566-568. PMID:22754789, PMCID: [PMC3382885](#)
77. Bravo R, Pelayo-Katsanis LO, Shehab ZM, [Katsanis E](#). Diagnostic and Treatment Challenges for the Pediatric Hematologist Oncologist in Endemic Areas for Coccidioidomycosis. ***J Pediat Hematol Onc* 2012** Jul;34(5):389-94. PMID:22510771
78. Kopp LM, Gupta P, Pelayo-Katsanis L, Wittman B, [Katsanis E](#). Late effects in adult survivors of pediatric cancer: A guide for the primary care physician. ***Am J Med* 2012** Jul;125(7):636-41. PMID:22560808 (57 citations)



79. Centuori S, Larmonier C, LaCasse CJ, Hanke NT, Kartchner J, Janikashvili N, Trad M, Alizadeh D, Bonnotte B, Larmonier N, [Katsanis E](#). Myeloid-derived suppressor cells from tumor bearing mice impair TGF-beta-induced differentiation of CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> regulatory T cells from CD4<sup>+</sup>CD25<sup>-</sup>FoxP3<sup>-</sup> T cells. **J Leukocyte Biol** 2012 Nov;92(5):987-97. PMID:22891289, PMCID: [PMC3476240](#) (79 citations)
80. Hanke NT, Alizadeh D, [Katsanis E](#), Larmonier N. Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy. **Crit Rev Immunol** 2013 33(1):1-21. PMID:23510023, PMCID: [PMC3694804](#)
81. Alizadeh D, [Katsanis E](#), Larmonier N. The multifaceted role of Th17 lymphocytes and their associated cytokines in cancer. **Clin Dev Immunol (J Immunol Res)** 2013:957878. PMID:24454480, PMCID: [PMC3888704](#)
82. Graner MW, Romanoski A, [Katsanis E](#). The “peptidome” of tumor-derived chaperone-rich cell lysate (CRCL) reveals potential antigens that stimulate tumor immunity. **Int J Hyperther** 2013 Aug;29(5):380-9. PMID:23725202
83. Epple LM, Bemis LT, Cavanaugh RP, Skope A, Mayer-Sonnenfeld T, Frank C, Olver CS, Lencioni AM, Dusto NL, Tal A, Har-Noy M, Lillehei KO, [Katsanis E](#), Graner MW. Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumor-derived chaperone-rich cell lysate (CRCL) vaccine. **Int J Hyperther** 2013 Aug;29(5):390-8. PMID:23786302
84. Alizadeh D, [Katsanis E](#), Larmonier N. Chemotherapeutic targeting of myeloid-derived suppressor cells **Oncoimmunol** 2014 Jan 1;3(1):e273381-3. PMID:24653963, PMCID: [PMC3960296](#)
85. Alizadeh D, Trad M, [Katsanis E](#), Larmonier N. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T cell transfer in breast cancer. **Cancer Res** 2014 Jan;74(1):104-18. PMID:24197130, PMCID: [PMC3896092](#) (290 citations)
86. Karski EE, Dvorak CC Leung W, Miller W, Shaw PJ, Qayed M, [Katsanis E](#), Feusner JH. Treatment of hepatoblastoma with high dose chemotherapy and stem cell rescue: The Pediatric Blood and Marrow Transplant Consortium experience and review of the literature. **J Pediatr Hematol Oncol** 2014 Jul;36(5):362-8. PMID:24577552
87. Hanke NT, LaCasse CJ, Larmonier C, Trad M, Janikashvili N, Bonnotte B, [Katsanis E](#), Larmonier N. PIAS1 and STAT-3 impair the tumoricidal of IFN-γ-stimulated mouse dendritic cells generated with IL-15. **Eur J Immunol** 2014 Aug;44(8):2489-99. PMID:24777831, PMCID: [PMC4141036](#)
88. Zeng Y, Stokes J, Hahn S, Hoffman E, [Katsanis E](#). Activated MHC-mismatched T helper-1 lymphocyte infusion enhances graft-versus-leukemia with limited graft-versus-host disease. **Bone Marrow Transplant** 2014 Aug;49(8):1076-83. PMID:24777185
89. Lund TC, Cathey SS, Miller WP, Eapen M, Andreansky M, Dvorak CC, Davis JH, Dalal JD, Devine SM, Eames GM, Ferguson WS, Giller RH, He W, Kurzberg J, Krance R, [Katsanis E](#), Lewis VA, Sahdev I, Orchard PJ. Outcomes after hematopoietic stem cell transplant for children with I-cell disease. **Biol Blood Marrow Transplant** 2014 Nov;20(11):1847-51. PMID:25016194, PMCID: [PMC4194244](#)
90. Menon NM, [Katsanis E](#), Khalpey Z, Whitlow P. Pediatric secondary chronic myeloid leukemia following cardiac transplantation for anthracycline-induced cardiomyopathy. **Pediatr Blood Cancer** 2015 Jan;62(1):166-8. PMID:25175922





91. Trad M, Gautheron A, Fraszczak J, Alizadeh D, Larmonier C, LaCasse C, Centuori S, Audia S, Samson M, Ciudad M, Bonnefoy F, Lemaire-Ewing S, [Katsanis E](#), Perruche S, Saas P, Larmonier N, Bonnotte B. T-lymphocyte inhibition by tumor-infiltrating dendritic cells involves involves ectonucleotidase CD39 but not arginase-1. **Biomed Res Int** 2015;2015:891236. PMID:26491691, PMCID: [PMC4605267](#)
92. Graner M, Lillehei KO, [Katsanis E](#). Endoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccines. **Front Oncol** 2015 Jan;4:379. PMID:25610811, PMCID: [PMC4285071](#)
93. Houghtelin A, Kopp LM, Pelayo-Katsanis L, Kuo H, Yeager A, [Katsanis E](#). Extramedullary breast relapse of acute lymphoblastic leukemia controlled with a second allogeneic/autologous hematopoietic cell transplant. **J Adolesc Young Adult Oncol** 2015 Mar;4(1): 50-53. PMID:26812431
94. Zeng Y, [Katsanis E](#). The complex pathophysiology of idiopathic aplastic anemia. **Clin Exp Immunol** 2015 Jun;180(3):361-70. PMID:25683099, PMCID: [PMC25683099](#) (105 citations)
95. Kopp LM, [Katsanis E](#). Targeted immunotherapy for pediatric solid tumors. **Oncoimmunol** 2016 Mar 1;5(3):e1087637-8. PMID:27141344, PMCID: [PMC4839383](#)
96. Menon NM, Jenkins LM, Cui H, Anwer F, Yeager AM, [Katsanis E](#). Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia. **Ann Hematol** 2016 Mar;95(4):637-44. PMID:26787415
97. Stokes J, Hoffman EA, Zeng Y, Larmonier N, [Katsanis E](#). Post-transplant bendamustine reduces graft versus host disease while preserving graft versus leukemia in experimental haploidentical bone marrow transplantation. **Br J Haematol** 2016 Jul;174(1):102-16. PMID:27030315, PMCID: [PMC4917459](#)
98. [Katsanis E](#), Sapp LN, Pelayo-Katsanis L, Whitney K, Zeng Y, Kopp LM. Alternative donor hematopoietic cell transplantation conditioned with myeloablative busulfan fludarabine and melphalan is well tolerated and effective against high-risk myeloid malignancies. **J Pediatr Hematol Oncol** 2016 Nov;38(8):e315-e318. PMID:27467368
99. Okolo ON, [Katsanis E](#), Yun S, Reveles CY and Anwer F. Allogeneic transplant in ELANE, MEFV mutation positive severe cyclic neutropenia: review of prognostic factors for secondary severe events. **Case Rep Hematol** 2017 2017:5375793. PMID:28197346, PMCID: [PMC5286543](#)
100. Zeng Y, Hahn S, Stokes J, Hoffman E, Proytcheva M, Schmelz M, Chernoff J, [Katsanis E](#). Pak2 regulates myeloid derived suppressor cell development in mice. **Blood Adv** 2017 Oct 10; 1(22):1923-33. PMID:29296839, PMCID: [PMC5728145](#)
101. Zeng Y, [Katsanis E](#). Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation. **Bone Marrow Transplant** 2017 Dec;52(12):1671-1673. PMID:28920946
102. Graetz R, Meyer R, Shehab K, [Katsanis E](#). Successful resolution of hyperammonemia following hematopoietic cell transplantation with directed treatment of *Ureaplasma parvum* infection. **Transpl Infect Dis** 2018 Apr;20(2):e12839. PMID:29359847
103. Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A, Hamerschlak N, Kharfani-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, [Katsanis E](#), Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, Fenske TS, Smith SM, Sureda A, Olteanu H, Hamadani M. Allogeneic Hematopoietic



- Cell Transplantation for Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A CIBMTR Analysis. **Br J Haematol** 2018 Sep;182(6):916-920. PMID:28771676, PMCID: [PMC5796874](#). (53 citations)
104. [Katsanis E](#), Sapp LN, Varner N, Koza S, Stea B, Zeng Y. Haploidentical bone marrow transplantation with post-transplant cyclophosphamide/bendamustine in pediatric and young adult patients with hematologic malignancies. **Biol Blood Marrow Transplant** 2018 Oct; 24(10):2034-2039. PMID:29908231, [PMCID: PMC7556327](#).
  105. Doane CJ, Patil K, Hoffman EA, Stokes J, [Katsanis E](#), Besselsen DG. Supernumerary incisors in bone marrow transplanted CB6F1 mice conditioned with chemotherapy and total body irradiation. **Comp Med** 2018 Oct 1;68(5):349-352. PMID:30208992, [PMCID: PMC6200027](#).
  106. Graff RM, Kunz HE, Agha NH, Baker FL, Markofski MM, LaVoy EC, Laughlin M, [Katsanis E](#), Bond RA, Bollard CM, Simpson RJ.  $\beta_2$ -adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8<sup>+</sup> T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans. **Brain Behav Immun** 2018 Nov;74:143-153. PMID:30172948, (64 citations)
  107. Stokes J, Hoffman EA, Molina MS, Eremija J, Larmonier N, Zeng Y, [Katsanis E](#). Bendamustine with total body irradiation limits murine graft versus host disease in part through effects on myeloid derived suppressor cells. **Biol Blood Marrow Transplant** 2019 Mar;25(3):405-416. PMID:30326280, [PMCID: PMC7571287](#).
  108. Nicholls L, Montez J, Pelayo-Katsanis L, [Katsanis E](#). Esophageal varices in adolescent and young adult males with acute lymphoblastic leukemia. **J Adolesc Young Adult Oncol** 2019 Apr;8(2):217-220. PMID:30335538
  109. Famoso JM, Grow JL, Laughlin BL, [Katsanis E](#), Stea B. The Impact of low dose cranial boost on the long-term Outcomes of adult patients with high-risk acute lymphoblastic leukemia undergoing total body irradiation and allogeneic hematopoietic stem cell transplantation. **Pract Radiat Oncol** 2019 May;9(3):e283-e289. PMID:30578956
  110. Macaraeg M, Proytcheva M, [Katsanis E](#). Transfusion independence after repeated haploidentical hematopoietic cell transplants in a patient with congenital dyserythropoietic anemia type II and hemosiderosis. **Pediatr Transplant** 2019 Dec;23(8):e13587. PMID:31529567
  111. Baker FL, Bigley AB, Agha NH, Pedlar C, O'Connor DP, Bond RA, Bollard CM, [Katsanis E](#), Simpson RJ. Systemic  $\beta$ -adrenergic receptor activation augments the ex vivo expansion and anti-tumor activity of V $\gamma$ 9V $\delta$ 2 T-cells. **Front Immunol** 2020 Jan 24;10:3082. PMID:32038628 [PMCID: PMC6993603](#)
  112. Agha NH, Mehta S, Rooney BV, Laughlin MS, Markofski MM, Pierson DL, [Katsanis E](#), Crucian BE, Simpson RJ. Exercise as a countermeasure for latent viral reactivation during long duration space flight. **FASEB J** 2020 Feb;34(2):2869-2881. PMID:31908052
  113. Simpson RJ, [Katsanis E](#). The immunological case for staying active during the COVID-19 pandemic. **Brain Behav Immun** 2020 Jul; 87:6-7. PMID:32311497, [PMCID: PMC7165095](#) (102 citations)
  114. Stokes J, Hoffman EA, Molina MS, Kummet N, Simpson RJ, Zeng Y, [Katsanis E](#). Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell dependent



- graft-versus-leukemia. *Oncoimmunol* **2020** Apr 30;9(1):1758011. PMID:32391190, PMCID: [PMC7199810](#)
115. [Katsanis E](#), Maher K, Roe D, Simpson RJ. Progressive substitution of post-transplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation. *eJHaem* **2020** May 26, 2020;1(1), 286-292. doi: [10.1002/jha2.20](#)
  116. [Katsanis E](#), Sapp LN, Cienfuegos-Reid S, Reddivalla N, Stea B. T-cell replete myeloablative haploidentical bone marrow transplantation is an effective option for pediatric and young adult patients with high-risk hematologic malignancies. *Front Pediatr* **2020** June 9, 8:282. PMID:32582591, PMCID: [PMC7295947](#)
  117. Molina MS, Stokes J, Hoffman EA, Eremija J, Zeng Y, Simpson RJ, [Katsanis E](#). Bendamustine conditioning skews murine host dendritic cells toward pre-cDC1s and reduces graft-versus-host disease independently of Batf3. *Front Immunol* **2020** July 16;11:1410. PMID:32765499, PMCID: [PMC7378358](#)
  118. Kunz HE, Agha NH, Hussain M, Smith K, Mylabathula P, Diak D, Baker FL, O'Connor DP, Bond R, [Katsanis E](#), Bollard C, Simpson RJ. The effects of  $\beta 1$  and  $\beta 1+\beta 2$  adrenergic receptor blockade on the exercise-induced mobilization and *ex vivo* expansion of virus-specific T-cells: implications for cellular therapy and anti-viral immune effects of exercise. *Cell Stress Chaperones* **2020** Nov;25(6):993-1012. PMID:32779001, PMCID: [PMC7591642](#)
  119. Smith J, Kumar A, Stanton NA, [Katsanis E](#). Concurrent application of blinatumomab and haploidentical donor leukocyte infusions for refractory primary mediastinal large B-cell lymphoma. *The Adv Hematol* **2021** Feb 23;12:2040620721994348. PMID:33747421, PMCID: [PMC7905714](#)
  120. Stokes J, Molina MS, Hoffman EA, Simpson RJ, Zeng Y, [Katsanis E](#). Immunomodulatory effects of bendamustine in hematopoietic cell transplantation. *Cancers* **2021** Apr 3;13(7):1702. PMID:33916711, PMCID: [PMC8038415](#)
  121. Stanley K, Hanmod S, Simpson RJ, [Katsanis E](#). Haploidentical hematopoietic cell transplantation is even more advantageous during the COVID-19 pandemic. *Pediatr Transplant* **2021** May;25(3):e14004. PMID:33729657, PMCID: [PMC8250374](#)
  122. Molina MS, Hoffman EA, Stokes J, Kummet N, Smith KA, Baker FL, Zúñiga T, Simpson RJ, [Katsanis E](#). Regulatory dendritic cells induced by bendamustine, are associated with enhanced Flt3 signaling and alloreactive T-cell death. *Front Immunol* **2021** Jun 24;12:699128. PMID:34249005, PMCID: [PMC8264365](#)
  123. Gustafson MP, Wheatley-Guy CM, Rosenthal AC, Gastineau DA, [Katsanis E](#), Johnson BD, Simpson RJ. Exercise and the immune system: taking steps to improve responses to cancer immunotherapy. *J Immunother Cancer* **2021** Jul;9(7):e001872. PMID:34215686, PMCID: [PMC8256759](#)
  124. Pariury H, Truscott L, [Katsanis E](#). Have CD19-directed immunotherapy and haploidentical hematopoietic cell transplantation transformed pediatric B-cell acute lymphoblastic leukemia into a chronic disease? *Oncoimmunol* **2021** Jul 25;10(1):1956125. PMID:34367735, PMCID: [PMC8312595](#)
  125. Sharma A, Huang S, Li Y, Brooke JR, Ahmed I, Allewelt HB, Amrolia P, Bertaina A, Bhatt NS, Bierings MB, Bies J, Brisset C, Brondon JE, Dahlberg A, Dalle J, MD, Eissa H, Fahd M, Gassas A, Gloude NJ, Goebel WS, Goekerman ES, Harris K, Ho R, Hudspeth MP, Huo JS, Jacobsohn D,



- Kasow KA, Katsanis E, Kaviyany S, Keating AK, Kernan NA, Ktena YP, Lauhan CR, López-Hernandez G, Martin P, Myers KC, Naik S, Olaya-Vargas A, Onishi T, Radhi M, Ramachandran S, Ramos K, Rangarajan HG, Roehrs PA, Sampson ME, Shaw P, Skiles JL, Somers K, Symons H, de Tersant M, Uber AP, Versluys B, Cheng C, Triplett BM. Outcomes of pediatric patients with therapy-related myeloid neoplasms. ***Bone Marrow Transplant*** 2021 Sep 3 PMID:34480120
126. Baker FL, Smith KA, Zúñiga T, Batatinha H, Niemiro GM, Pedlar CR, Burgess SC, Katsanis E, Simpson RJ. Acute exercise increases immune responses to SARS CoV-2 in a previously infected man. ***Brain Behav Immun Health*** 2021 Sep 8:100343. PMID:34514439, PMCID: PMC8423674
  127. Smith J, Hass-Alfonso J, Reddivalla N, Angulo P. Katsanis E. Haploidentical bone marrow transplantation in two brothers with Wiskott-Aldrich syndrome using their father as the donor ***Front Pediatr*** (in press)
  128. Rangarajan HG, Stanek JR, Abdel-Azim H, Modi A, Haight A, McKinney CM, McKeone DJ, Buchbinder DK, Katsanis E, Abusin GA, Ahmed I, Law J, Galvez Silva J, Mallhi KK, Burroughs LM, Shah N, Shaw PJ, Greiner R, Shenoy S, Pulsipher MA, Abu-Arja R. Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia. A Report from the Pediatric Transplant and Cellular Therapy Consortium (PTCTC). (Submitted)
  129. Niemiro GM, Coletta AM, Agha NH, Mylabathula PL, Baker FL, Brewster AM, Bevers TB, Fuentes-Mattei E, Basen-Engquist K, Katsanis E, Gilchrist SC, Simpson RJ. Salutary effects of moderate but not high intensity aerobic exercise training on the frequency of peripheral T-cells associated with immunosenescence in older women at high risk of breast cancer: a randomized controlled trial. (Submitted)
  130. Molina MS, Hoffman EA, Stokes J, Kummet N, Simpson RJ, Katsanis E. Murine precursor to type 1 conventional dendritic cells induce tumor cytotoxicity and activation of the PD-1/PD-L1 pathway. (Submitted)
  131. Batatinha H, Baker FL, Smith KA, Zúñiga TM, Pedlar C, Burgess S, Katsanis E, and Simpson RJ. Recent COVID-19 vaccination is associated with modest increases in the physiological responses to graded exercise. (Submitted)

\*=shared senior authorship  
 (#)=publications with >50 citations



## BIBLIOGRAPHY: Book Chapters

---

1. Katsanis E. Immunobiology and biologic therapy of neuroblastoma. In Bertino JR, ed., **Encyclopedia of Cancer 1997**, 1st ed., Academic Press, San Diego CA. 1142-1154.
2. Katsanis E, Whitesell L. Neuroblastoma. In Bertino JR, ed., **Encyclopedia of Cancer 2002**, 2nd ed., Academic Press, San Diego CA. 315-321.
3. Graner MW, Katsanis E. Chaperone proteins/Heat shock proteins as anticancer vaccines. In Morse M.A., Clay TM, Lyerly HK, ed., **Handbook of Cancer Vaccines 2004**, Humana Press, Totowa NJ. 297-316.
4. Larmonier N, Katsanis E. Dendritic Cells for Cancer Immunotherapy. In Danquah MK, Mahato RI ed., **Emerging Trends in Cell and Gene Therapy 2013**, Springer Science, New York NY. 251-270.
5. Kopp LM, Katsanis E. Neuroblastoma. In **Reference Module in Biomedical Sciences 2015**, Elsevier Science Direct, New York/Amsterdam
6. Kopp LM, Katsanis E. Immunotherapy for pediatric solid tumors. In Rezaei N ed., **Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors 2015**, Springer-Verlag Berlin/Heidelberg 47-67.
7. Graner M, Lillehei KO, Katsanis E. Endoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccines. In Paul Eggleton P, Michalak M, and Bremer E, ed., **Endoplasmic Reticulum and Its Role in Tumor Immunity, 2016** Frontiers eBook Lausanne, Switzerland. 90-101.
8. Ramos K, Katsanis E. Recent advances in haploidentical hematopoietic cell transplantation for pediatric hematologic malignancies. In Rezaei N ed., **Cancer Immunology: Bench to Bedside Immunotherapy of Cancers 2021**, 2<sup>nd</sup> ed, Springer Nature Switzerland 157-168.

## BIBLIOGRAPHY: Non-Peer-Reviewed Publications

---

1. Katsanis E, Malone B, Smith C. Recurrent epistaxis. *Pediatr Update* 1990 Vol. 10, No. 12
2. Katsanis E, Larmonier N. Combining cancer vaccines and T lymphocyte modulation. *World Hell Biomed News* 2012 Jan 3(1):10-14

## BIBLIOGRAPHY: Abstracts

---

1. Katsanis E, Tolis G., Abou-Abdallah M. Male reproductive function in patients with hyperprolactinemia. Presented at the First International Symposium on Hyperprolactinemia and Reproduction, Mexico City, October 1981.
2. Katsanis E, Mercer S. Crohn's disease in children and adolescents. Presented at the Eastern Ontario Paediatric Association, Kingston, Ontario, May 1984.



3. Katsanis E., Luke K.H., Hsu E. Hemoglobinopathies in children from Southeast Asia. Presented at the Eastern Ontario Paediatric Association, Smiths Falls, Ontario, May 1985.
4. Katsanis E., Hsu E., McKee J.A. Association of sickle hemoglobinopathies with systemic lupus erythematosus. Presented at the Canadian Paediatric Society and the Canadian Society for Clinical Investigation, Vancouver, British Columbia, September 1985. Clin Invest Med 8(3):A174, 1985.
5. Katsanis E., Hsu E., Luke K.H. Isolated testicular relapse in acute lymphoblastic leukemia following bone marrow transplantation. Presented at the Royal College of Physicians and Surgeons of Canada and the Canadian Hematology Society, Vancouver, British Columbia, September 1985. Clin Invest Med 8(3):A122, 1985.
6. Katsanis E., Luke K. H., Hsu E., Yates J. Hemoglobin E: A frequently encountered disorder among Southeast Asian children in Canada. Presented at the Canadian Paediatric Society, Toronto, Ontario, September 1986. Clin Invest Med 9(3):A136, 1986.
7. Katsanis E., Luke K.H., D'Astous J., Hsu E., Jones H. Surgical synovectomy for severe arthropathy in two hemophilia A children with low titre inhibitors. Presented at the Royal College of Physicians and Surgeons of Canada and the Canadian Hematology Society, Toronto, Ontario, September 1986. Clin Invest Med 9(3):A81, 1986.
8. Katsanis E., Luke K.H., Hsu E., Li M., Lillicrap D. Recurrent epistaxis in childhood; when is hemostatic evaluation warranted. Presented at the Eastern Ontario Paediatric Association, Kingston, Ontario, June 1987.
9. Katsanis E., Luke K.H., Hsu E., Li M., Lillicrap D. The prevalence and significance of mild bleeding disorders in children with recurrent epistaxis. Pediatr Res 23(4):341A, 1988.
10. Luke K.H., Katsanis E., Hsu E. Bleeding disorders in children with recurrent epistaxis. Presented at the Joint Chinese-Canadian Pediatric Societies, Beijing, People's Republic of China, November 1988.
11. Katsanis E., Shapiro R.S., Robison T.H., Kim T.H., Haake R., Ramsay N.K.C. Long-term follow-up of thyroid function in 77 patients following bone marrow transplantation. Proc Am Soc Clin Oncol 8:17, 1989.
12. Katsanis E., Loeffler C.M., Ochoa A.C., Anderson P.M. Murine pharmacokinetic studies following free and liposomal interleukin-2 administration. Presented at the Pediatric Fellows' Research Symposium, University of Minnesota, Minneapolis, Minnesota, April 1989.
13. Loeffler C.M., Ochoa A.C., Katsanis E., Anderson P.M., Leonard, A.S. Immunotherapy of hepatic metastases of murine adenocarcinoma using IL-2 liposomes. Presented at the 7th International Congress of Immunology, Berlin, Federal Republic of Germany, July 1989.
14. Katsanis E., Shapiro R.S., Robison T.H., Haake R., Kim T.H., Pescovitz O.H., Ramsay N.K.C. Thyroid dysfunction following bone marrow transplantation. Presented at the Northwestern Pediatric Society, Rochester, Minnesota, September 1989.
15. Anderson P.M., Katsanis E., Rich M.L., Leonard A.S., Loeffler C.M., Ochoa A.C. Immunoadjuvant studies of IL-2 liposomes against cancer: Murine pharmacokinetic and antitumor efficacy studies using intracavitary routes of administration. Presented at the UCLA Symposia on Molecular and Cellular Biology, Park City, Utah, January, 1990. J Cell Biochem Suppl 14B:93, 1990.



16. Katsanis E., Ochoa A.C., Bausero M.A., Loeffler C.M., Anderson P.M. Combination therapy of C1300 murine neuroblastoma with IL-2 liposomes, anti-GD2 monoclonal antibody and cyclophosphamide. Presented at the UCLA Symposia on Molecular and Cellular Biology, Park City, Utah, January, 1990. *J Cell Biochem Suppl* 14B:97, 1990.
17. Katsanis E., Ochoa A.C., Bausero M.A., Loeffler C.M., Anderson P.M. Cyclophosphamide enhances LAK activity against neuro-2a murine neuroblastoma. Presented at the American Association for Cancer Research, Washington, D.C., May 1990. *Proc Am Assoc Cancer Res* 31:270, 1990.
18. Anderson P.M., Weisdorf D.J., Hasz D.E., Rich M.L., Ochoa A.C., Katsanis E. Bone marrow transplant patients have significantly enhanced cytolytic activity but inferior proliferation of peripheral blood mononuclear cells stimulated with anti-CD3 + interleukin-2. Presented at the American Association for Cancer Research, Washington, D.C., May 1990. *Proc Am Assoc Cancer Res* 31:269, 1990.
19. Katsanis E., Ochoa A.C., Bausero M.A., Anderson P.M. Effect of interleukin-2 and cyclophosphamide on the antitumor immune response against murine neuroblastoma. Presented at the American Society of Pediatric Hematology/Oncology, Chicago, Illinois, September 1990.
20. Anderson, P.M., Katsanis E., Hasz D., Weisdorf D. Development of specific T cell mediated anti-B lineage acute lymphoblastic leukemia cellular immunity using in vivo interleukin-2 after autologous bone marrow transplant. Presented at the American Society of Pediatric Hematology/Oncology, Chicago, Illinois, September 1990.
21. Weisdorf D.J., Anderson P.M., Katsanis E., Kersey J.H., Ramsay N.K.C. Interleukin-2 plus autologous marrow transplantation for acute lymphoblastic leukemia: In vivo activation of cytolytic lymphoid effectors. Presented at the American Society of Hematology, Boston, Massachusetts, December 1990. *Blood* 76(suppl 1):572a, 1990.
22. Anderson P.M., Hasz D.E., Rich M.L., Sencer S.F., Katsanis E., Loeffler C.M., Ochoa A.C. Studies of interleukin-2 liposomes, a cytokine formulation with depot characteristics and adjuvant properties. Presented at the American Society of Pediatric Hematology/Oncology, Chicago, Illinois, September 1991.
23. Katsanis E., Bausero M.A., Blazar B.R. Interferon- $\gamma$  enhances lysis of murine neuroblastoma by upregulating tumor cell adhesion molecules. Presented at the American Association for Cancer Research, San Diego, California, May 1992. *Proc Am Assoc Cancer Res* 33:296, 1992.
24. Katsanis E., Orchard P.J., Bausero M.A., Gorden K.B., Mclvor R.S., Blazar B.R. Retroviral vector mediated IL-2 gene transfer into murine neuroblastoma cells reduces their tumorigenicity. Presented at the American Society of Pediatric Hematology/Oncology, Chicago, Illinois, September 1992. *Proc Am Soc Pediatr Hematol Oncol* 1:12, 1992.
25. Weisdorf D.J., Katsanis E., Verfaillie C., Ramsay N.K.C., Garrison L., Blazar B.R. Interleukin-1 $\alpha$  after autologous marrow transplantation for lymphoma/Hodgkin's disease: clinical and hemalogic effects. Presented at the American Society of Hematology, Anaheim, California, December 1992. *Blood* 80(suppl 1):333a, 1992.
26. Katsanis E., Orchard P.J., Bausero M.A., Gorden K.B., Mclvor R.S., Blazar B.R. Decreased tumorigenicity of murine neuroblastoma after retroviral vector mediated IL-2 gene transfer and expression. Presented at the Keystone Symposia on Molecular and Cellular Biology, Taos, New Mexico, March 1993. *J Cell Biochem Suppl* 17D:119, 1993.



27. Orchard P.J., Katsanis E., Gorden K.B., May C., Mclvor R.S., Blazar B.R. Retroviral vector mediated gene transfer of IL-2 reduces tumorigenicity in murine lymphoma. Presented at the Keystone Symposia on Molecular and Cellular Biology, Taos, New Mexico, March 1993. *J Cell Biochem Suppl* 17D:120, 1993.
28. Katsanis E., Blazar B.R., Xu Z., Barrett B.A., Bausero M.A., Anderson P.M., Orchard P.J., Weisdorf D.J., Ochoa A.C. In vivo proliferation, distribution and anti-tumor effect of anti-CD3 activated splenocytes following syngeneic murine bone marrow transplantation. Presented at the American Association for Cancer Research, Orlando, Florida, May 1993. *Proc Am Assoc Cancer Res* 34:469, 1993.
29. Bausero M.A., Panoskaltis-Mortari A., Xu Z., Blazar B.R., Katsanis E. Effective immunization against murine neuroblastoma using transduced tumor cells secreting GM-CSF and interferon- $\gamma$ . Presented at the International Conference on Gene Therapy of Cancer, San Diego, California, November 1995. *Cancer Gene Ther*, 2: 309, 1995.
30. Katsanis E., Xu Z., Panoskaltis-Mortari A., Hasz D.E., Weisdorf D.J., Widmer M.B., Blazar B.R. IL-15 administration following syngeneic murine bone marrow transplantation for lymphoma improves survival and has decreased toxicity when compared to IL-2. Presented at the American Society of Hematology, Seattle, Washington, December 1995. *Blood* 86(suppl 1):571a, 1995.
31. Saltzman D.A., Katsanis E., Heise C.P., Hasz D.E., Vigdorovich V., Curtiss R.E., Anderson P.M., Leonard A.S. Anti-tumor mechanisms of attenuated salmonella typhimurium containing the gene for human IL-2. Presented at the American Pediatric Surgical Association. San Diego, California, May 1996.
32. Saltzman D.A., Katsanis E., Heise C.P., Hasz D.E., Kelly S.M., Curtiss R.E., Anderson P.M., Leonard A.S. Hepatic and splenic colonization by an attenuated salmonella typhimurium strain containing the gene for human IL-2: A novel anti-tumor agent. Presented at the Surgical Infection Society, Milwaukee, Wisconsin, April 1996.
33. Miller J.S., Tuck J., Pierson B.A., Weisdorf D.J., McGlave P.B., Blazar B.R., Katsanis E., Verfaillie C., Lebkowski J., Radford J., Burns L. Low dose subcutaneous interleukin-2 after autologous BMT safely augments natural killer activity. Presented at the International Society of Experimental Hematology, New York City, New York, August 1996. *Exp Hematol* 24:1090, 1996.
34. Sanan A., LeBien T.W., Katsanis E. Transduction of granulocyte-macrophage colony stimulating factor abolishes the tumorigenicity of the c6 rat glioma cell line. Presented at the Congress for Neurological Surgeons, Montreal, Quebec, October 1996. *Neurosurgery* 39:648, 1996.
35. Davies S.M., Wagner J.E., Defor T., Blazar B.R., Katsanis E., Kersey J.H., Orchard P.J., McGlave P.B., Weisdorf D.J., Ramsay N.K.C. Unrelated donor bone marrow transplantation for children and adolescents with aplastic anemia or myelodysplasia. Presented at the American Society of Hematology, Orlando, Florida, December 1996. *Blood* 88(suppl 1):267a, 1996.
36. Miller J.S., Tessmer-Tuck J., Pierson B.A., Weisdorf D.J., McGlave P.B., Blazar B.R., Katsanis E., Verfaillie C., Burns L. Subcutaneous IL-2 after autologous BMT expands NK cells in vivo but requires ex vivo high-dose IL-2 for maximal activation. Presented at the American Society of Hematology, Orlando, Florida, December 1996. *Blood* 88(suppl 1):609a, 1996.
37. He L., Graner M., Katsanis E. Dendritic cells induce T cell responses against bcr/abl<sup>+</sup> chronic myelogenous leukemia. Presented at the Keystone Symposia on Molecular and Cellular Biology, Cellular and Molecular Biology of Dendritic Cells, Santa Fe, New Mexico, March 1998.





38. Bulte J.W.M, Verkuyl J.M., Herynek V., Katsanis E., Brocke S., Holla M., Frank J.A. Magnetoimmunodetection of (transfected) ICAM-1 gene expression. Presented at the 6th International Society of Magnetic Resonance in Medicine (ISMRM) Conference, Sydney, Australia, April 1998.
39. Graner M., Romney D., He L., Katsanis E. Purification of heat shock and chaperone proteins from A20 murine lymphoma. Presented at the Cold Spring Harbor Meeting on Molecular Chaperones and the Heat Shock Response. Cold Spring Harbor, New York, May 1998.
40. Yorgin P.D., Hartson S.D., Fella A.M., Scroggins B.T., Huang W., Matts R.L., Katsanis E., Couchman J.M., Whitesell L. Effect of the Hsp90 binding drug geldanamycin on T cell kinases and cellular function. Presented at the Cold Spring Harbor Meeting on Molecular Chaperones and the Heat Shock Response. Cold Spring Harbor, New York, May 1998.
41. Bulte J.W.M, Brooks R.A., Moskowitz B., Verkuyl J.M., Herynek V., Brocke S., Xu S., Jordan E.K., Bryant L.H., Katsanis E., Frank J.A. Antiferromagnetic nanoparticles as contrast agents for magneto-immunodetection of inflammation-specific adhesion molecules. Presented at the Second International Conference on Scientific and Clinical Applications of Magnetic Carriers, Cleveland, Ohio, May 1998.
42. Graham M.L., Katsanis E., Shapiro T.W., Hutter J.J., Martin P., Kurtzberg J.A. Busulfan and melphalan as preparative therapy for BMT in childhood leukemias. Presented at the American Society of Hematology, Miami, Florida, December 1998. Blood 92(suppl 1):128a, 1998.
43. Perentesis J., DeFor T.E., Neglia J.P., Katsanis E., Ramsay N.K. Successful autologous stem cell transplantation for high-risk pediatric solid tumors. Presented at the American Society of Clinical Oncology, Atlanta, Georgia, May 1999. ASCO Proceedings 18:159, 1999.
44. Katsanis E., Graner M., Raymond A., Akporiaye E. Augmentation of tumor lysate immunogenicity by enrichment of chaperone proteins using free solution isoelectric focusing. Presented at the Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer, Santa Fe, New Mexico, January 2000.
45. Akporiaye E., Mack V., He L., Katsanis E. Tumor-derived transforming growth factor-beta interferes with antigen-presenting functions of bone marrow-derived dendritic cells. Presented at the Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer, Santa Fe, New Mexico, January 2000.
46. Graner M.W., Raymond A., Akporiaye E., Katsanis E. Tumor-derived multiple chaperone enrichment by free solution-isoelectric focusing yields potent anti-tumor vaccines. Presented at the 2<sup>nd</sup> International Conference on Heat Shock Proteins in Immune Response, Farmington, Connecticut, October 2000. Cell Stress & Chaperones 5:386, 2000.
47. Tyszka E., Davis N., Graner M.W., Katsanis E. Tumor-derived chaperone proteins as anti-cancer vaccines in multiple modality cancer therapy. Presented at the American Association for Cancer Research, New Orleans, Louisiana, March 2001. Proc Am Assoc Cancer Res 42:970, 2001.
48. Zeng Y., Feng H., Whitesell L., Katsanis E. Dendritic cells mature in response to heat stressed apoptotic tumor cells and induce specific immunity in vivo. Presented at the American Association for Cancer Research, New Orleans, Louisiana, March 2001. Proc Am Assoc Cancer Res 42:978, 2001.
49. Feng H., Zeng Y., Ramaiya K., Whitesell L., Katsanis E. Stressed Apoptotic Tumor Cells Express Membrane Heat Shock Proteins and Elicit Tumor Specific Immunity. Presented at the American



- Association for Cancer Research, New Orleans, Louisiana, March 2001. Proc Am Assoc Cancer Res 42:2725, 2001.
50. Beliakoff J., Katsanis E., Whitesell L. Tyrphostin AG1024-Mediated Inhibition of Cellular Proliferation and Induction of Apoptosis in Neuroblastoma Cells. Presented at the American Association for Cancer Research, New Orleans, Louisiana, March 2001. Proc Am Assoc Cancer Res 42:4576, 2001.
  51. Feng H., Zeng Y., Graner M.W., Katsanis E. Exogenous heat shock proteins provide adjuvant effects on enhancing the immunogenicity of apoptotic tumor cells and inducing anti-tumor immunity. Presented at the American Association for Cancer Research, San Francisco, California, April 2002. Proc Am Assoc Cancer Res 43:2214, 2002.
  52. Feng H., Zeng Y., Graner M.W., Whitesell L., Katsanis E. Evidence for a novel, caspase 8-independent, Fas death domain-mediated apoptotic pathway. Presented at the American Association for Cancer Research, San Francisco, California, April 2002. Proc Am Assoc Cancer Res 43:3509, 2002.
  53. Zeng Y., Feng H., Graner M.W., Katsanis E. Dendritic cells loaded with tumor-derived multiple chaperone proteins enriched by free solution-isoelectric focusing induce significant protective immunity. Presented at the American Association for Cancer Research, San Francisco, California, April 2002. Proc Am Assoc Cancer Res 43:4836, 2002.
  54. Graner M.W., Zeng Y., Feng H., Whitesell L., Katsanis E. Tumor-derived multiple chaperone complexes are effective therapeutic vaccines against a variety of cancers. Presented at the Cold Spring Harbor Meeting on Molecular Chaperones and the Heat Shock Response, Cold Spring Harbor, New York, May 2002.
  55. Graner M.W., Zeng Y., Feng H., Katsanis E. Leukemia-derived chaperone-rich cell lysates activate dendritic cells and elicit therapeutic immunity against murine leukemia. Presented at the 3<sup>rd</sup> International Conference on Heat Shock Proteins in Immune Response, Farmington, Connecticut, October 2002.
  56. Feng H., Zeng Y., Graner M.W., Likhacheva A., Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate anti-tumor immunity. Presented at the 17<sup>th</sup> Meeting of the Society of Biological Therapy, La Jolla, California, November 2002. Journal of Immunotherapy 25:S25, 2002.
  57. Graner M.W., Zeng Y., Feng H., Katsanis E. Tumor-derived chaperone-rich cell lysates activate dendritic cells and elicit therapeutic immunity against a wide variety of cancers. Presented at the 17<sup>th</sup> Meeting of the Society of Biological Therapy, La Jolla, California, November 2002. Journal of Immunotherapy 25:S22, 2002.
  58. Katsanis E., Zeng Y., Graner M.W. Leukemia-derived chaperone-rich cell lysates (CRCL) provide bcr-abl specific immunity. Presented at the Keystone Symposia on Basic Aspects of Tumor Immunology, Keystone, Colorado, February 2003.
  59. Zeng Y., Graner M.W., Feng H., Katsanis E. Leukemia-derived chaperone-rich cell lysates (CRCL) provide bcr-abl specific immunity. Presented at the American Society of Hematology, San Diego, California December 2003. Blood 102:655a, 2003.



60. Zeng Y., Graner M.W., Feng H., Li G., Katsanis E. Imatinib mesylate effectively combines with chaperone-rich cell lysate loaded dendritic cells to treat bcr-abl+ murine leukemia. *Blood* 102:322b, 2003.
61. Davis J.M., Romanoski M.A., Likhacheva A., Raymond A., Brandenberger J., Graner M.W., Katsanis E. The immunosuppressive effects and biochemistry of tumor expressed albumin. Presented at the American Association for Cancer Research Meeting, Orlando, Florida, March 2004. *Proc Am Assoc Cancer Res* 45:2172, 2004.
62. Kislin K. L., Graner M.W., Katsanis E. Peptide-loaded chaperone-rich cell lysates may enhance the effectiveness of anti-cancer vaccines. Presented at the American Association for Cancer Research, Orlando, Florida, March 2004. *Proc Am Assoc Cancer Res* 45:5457, 2004.
63. Akporiaye E., Ramanathapuram L., Kobie J.J., Katsanis E., Graner M. Cytoreduction and immunostimulation: Properties of  $\alpha$ -tocopheryl succinate that enhance the effectiveness of dendritic cells in treating established murine lung cancer. Presented at the American Institute for Cancer Research, Washington DC, July 2004. *Journal of Nutrition* 134 (12): 3545s-3545s Suppl. S, 2004.
64. Li G., Zeng Y., Chen X., Sepassi M., Romanoski M.A., Thompson S., Graner M.W., Brewer M.A., Katsanis E. Human ovarian tumor-derived chaperone-rich cell lysates (CRCL) activate dendritic cells and elicit T cell responses in vitro. Presented at the 19<sup>th</sup> Meeting of the Society of Biological Therapy, San Francisco, California, December 2004. *Journal of Immunotherapy* 27 (6): S26-S27 2004.
65. Chen X., Zeng Y., Li G., Thompson S., Sepassi M., Romanoski M.A., Graner M.W., Katsanis E. Tumor-derived chaperone-rich cell lysate (CRCL) can be effectively combined with syngeneic bone marrow transplantation to treat bcr-abl<sup>+</sup> leukemia in a murine model. Presented at the American Society of Hematology, San Diego, California, December 2004. *Blood* 104:811a, 2004.
66. Zeng Y., Cai X., Larmonier N., Katsanis E. Chaperone Rich Cell Lysates (CRCL) activate innate immune responses. Presented at the Keystone Symposia on Inflammation and Cancer, Breckenridge, Colorado, February 2005.
67. Larmonier N., Zeng Y., Marron M., Thompson S., Katsanis E. Role of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells in the immune response to chaperone rich cell lysate (CRCL) -based vaccination against a BCR-ABL<sup>+</sup> leukemia. Presented at the Keystone Symposia on Basic Aspects of Tumor Immunology, Keystone, Colorado, March 2005.
68. Cai X., Zeng Y., Marron M., Katsanis E. Tumor-derived chaperone rich cell lysates (CRCL) activate the innate immune system. Presented at the American Association for Cancer Research Meeting, Anaheim, California, April 2005. *Proc Am Assoc Cancer Res* 46:6048, 2005.
69. Kislin K.L., Graner M.W., Marron M.T., Katsanis E. Chaperone-rich cell lysate (CRCL) possesses a high carrying capacity for antigenic peptides leading to enhanced CTL activation. Presented at the American Association for Cancer Research Meeting, Anaheim, California, April 2005. *Proc Am Assoc Cancer Res* 46:5169, 2005.
70. Bleifuss E., Thompson S., Milani V., Graner M, Noessner E., Katsanis E., Issels R. Chaperone rich cell lysates (CRCL) as human anti tumour vaccines. Presented at the 22<sup>nd</sup> meeting of the European Society for Hyperthermic Oncology, Graz, Austria, June 2005.



71. Andreansky S., Li G., Sepassi M., Katsanis E. A multi-chaperoned heat shock protein-based tumor vaccine can generate humoral immunity in a HER-2/neu specific mouse tumor model. Presented at the Sixth Arizona Biosciences Research Symposium, Phoenix, Arizona, June 2006.
72. Cantrell J., Cai X., Zeng Y., Larmonier N., Katsanis E. Adjuvant Effect of CRCL: Activation of dendritic cells and macrophages. Presented at the Sixth Arizona Biosciences Research Symposium, Phoenix, Arizona, June 2006.
73. Kislin K.L., Graner M.W., Li G., Marron M., Katsanis E. Chaperone-Rich Cell Lysate embedded with exogenous peptides demonstrates enhanced anti-tumor activity. Presented at the Sixth Arizona Biosciences Research Symposium, Phoenix, Arizona, June 2006.
74. Larmonier N., Cantrell J., Katsanis E. Modulation of regulatory T lymphocyte-induced suppression of antigen presenting cells by tumor cell lysates enriched in chaperone proteins. Presented at the AACR Special Conference, Tumor Immunology: an integrated perspective, Miami, Florida, November 2006.
75. Li G, Andreansky S, Chen X, Penichet M, Katsanis E. Tumor-derived Chaperone-Rich Cell Lysate generates HER-2/neu specific immunity in a mouse model of breast cancer. Presented at the American Association for Cancer Research Meeting, Los Angeles, California, April 2007. Proc Am Assoc Cancer Res 48: LB-337, 2007.
76. Fiederlein R, Salamon D, Berg MP, Katsanis E, Graham M. Assessment of cell recovery obtained from cord blood units from different banks following thawing and cell washing. Presented at the American Association of Blood Banks Meeting, Anaheim, California, October 2007.
77. Graham ML., Andreansky M., Katsanis E. Wood T.S., Hutter J.J. Busulfan and single-dose melphalan as preparative therapy for infants and young children undergoing stem cell transplantation for leukemia: A single center experience. Biology of Blood and Marrow Transplantation 14:87-88, Suppl. 2. # 236 February 2008
78. Fraszczak J, Trad M, Dominique C, Janikashvili N, Katsanis E, Bonnotte B, and Larmonier N. Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells. Club Francophone des Cellules Dendritiques, Paris, France, March 2009.
79. Situ E, Katsanis E, Larmonier N. Influence of imatinib mesylate on bone marrow-derived dendritic cells. J Invest Med. Volume: 58 Issue: 1 Page: 193, #313, Jan 2010.
80. Wright J, Larmonier N, Katsanis E. Conversion inhibition of naive T lymphocytes into regulatory T cells by killer dendritic cells. J Invest Med. Volume: 58 Issue: 1 Page: 216, #395, Jan 2010.
81. LaCasse CJ, Janikashvili N, Katsanis E, Larmonier N. Th-1 lymphocytes promote dendritic cell tumoricidal activity. AACR Tumor Immunology: Basic and Clinical Advances conference. Miami, Florida December 2010.
82. Har-Noy M, Lausoontornsiri W, Or R, Katsanis E. Response of HER2+ breast cancer patients to allogeneic cell immunotherapy. J Clin Oncol 30, 2012 (suppl; abstr e13013)
83. Janikashvili N, LaCasse C, Hanke N, Gautheron A, Trad M, Ciudad M, Katsanis E, Bonnotte B and Larmonier N. IFN- $\gamma$  promotes mouse bone-marrow dendritic cell cytotoxic function through STAT-1. Annual congress on Dendritic Cells (Club Francophone des Cellules Dendritiques, CFCD), Pasteur Institute, Paris, France, December 2012.



84. Trad M, Janikashvili N, Fraszczak J, Larmonier C, LaCasse C, Alizadeh D, Centuori S, Bonnefoy F, Perruche S, Katsanis E, Larmonier N\* and Bonnotte B\*. Immunosuppressive function of tumor-infiltrating dendritic cells mediated by exo-enzyme CD39. Annual congress on Dendritic Cells (Club Francophone des Cellules Dendritiques, CFCD), Pasteur Institute, Paris, France, December 2012.
85. Alizadeh D, Trad M, Hanke N, Larmonier C, Bonnotte B, Katsanis E, Larmonier N. Doxorubicin eliminates tumor-induced myeloid-derived suppressor cells and enhances T-helper lymphocyte-based immunotherapy in a murine breast cancer model. Presented at the American Association for Cancer Research Meeting, Washington, DC, April 2013. *Proc Am Assoc Cancer Res* 2013, 54: 4740.
86. Alizadeh D, Katsanis E, Larmonier N. Role of reactive oxygen species in doxorubicin-induced apoptosis of myeloid-derived suppressor cells. Presented at the American Association for Cancer Research Meeting, San Diego, CA, April 2014. *Proc Am Assoc Cancer Res* 2014, 74(19 Suppl): Abstract # 150.
87. Jenkins LM, Menon NM, Katsanis E. Factors associated with improved outcomes after second hematopoietic cell transplantation in patients with leukemia. Presented at the Third Annual Joint ASPHO/PBMTC Meeting, Phoenix, AZ, May 2015. *Pediatr Blood Cancer* 2015, June;62(Suppl 2):111.
88. Grow JL, Stea B, Katsanis E. Treatment of pediatric CNS leukemia with cranial or craniospinal boost in conjunction with total body irradiation as part of the conditioning regimen for bone marrow transplantation. Presented at the American Society for Radiation Oncology Meeting, Boston, Massachusetts September 2016. *Int J Radiat Oncol Biol Phys*. 2016 Oct 1;96(2S):S166
89. Zeng Y, Hahn S, Stokes J, Hoffman E, Chernoff J, Katsanis E. Pak2 regulates MDSC development and function. Presented at the American Society of Hematology Meeting, San Diego, CA, December 2016. *Blood* 2016, 128(22) Abstract #705.
90. JM Famoso JM, JL Grow JL, B Laughlin B, E Katsanis E, B Stea S. Long-Term Outcomes of Adult Patients with High-Risk Acute Lymphoblastic Leukemia Undergoing Total Body Irradiation with or without Whole Brain Boost. Presented at the American Society for Radiation Oncology Meeting, San Antonio, Tx Oct 2018. *Int Radiat Oncol Biol Phys* 2018 Nov 1;102 (3), e253
91. Molina MS, Stokes J, Hoffman E, Eremija J, Zeng Y, Katsanis E. Bendamustine Conditioning Induces Phenotypic and Functional Changes in Host Antigen-Presenting Cells Which May Confer Protection Against GvHD. Presented at the American Association of Immunologists Annual Meeting, Austin TX, May 2018. *J Immunol* May 1, 2018, 200 (1 Supplement) 55.17
92. Hoffman EA, Stokes J, Molina MS, Katsanis E. Bendamustine with total body irradiation limits murine graft versus host disease in part via myeloid-derived suppressor cells. Presented at the American Society of Hematology Meeting, San Diego, CA, December 2018. *Blood* 2018, 132:2040.
93. Molina MS, Stokes J, Hoffman EA, Katsanis E. Bendamustine Conditioning Alters Host Dendritic Cell Composition and Function *Blood* 2018, 132:5670.
94. Durer S, Durer C, Jamil F, Selene II, Malik MN, Rafae A, Abu Zar M, Kamal A, Ijaz A, Usman M, Khan AY, Aby Jose I, Tariq MJ, Katsanis E, Anwer F. The Comparison of Unmanipulated Bone Marrow Versus Peripheral Blood Haploidentical Stem Cell Transplantation in Adult Acute Leukemia: A Systematic Review and Meta-Analysis. *Blood* 2018 132:5768



95. Durer S, Durer C, Katsanis E, Comba IY, Jamil F, Aslam S, Shah Z, Malik MN, Selene II, Fraz MA, Jose JA, Qureshi A, Yasir M, Amin SN, Anwer F. Outcomes of T-Cell Depleted Haploidentical Peripheral Blood Stem Cell Transplantation for Adult Acute Leukemia: A Meta-Analysis. *Blood* 2018 132:5779
96. Katsanis E, Stokes J, Hoffman EA, Maher K, Kodali M, Anwer F, McBride A, Roe D, Zeng Y, Simpson R. A Phase I Study of Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide and/or Bendamustine. Presented at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR, Houston TX, February 2019. *Biol Blood Marrow Transplant* 2019 25(3),S224.
97. J Faulkner J, J Eremija J, Katsanis E. Influence of microbiome changes on anti-tumor response. Presented at the Western Medical Research Conference, Carmel, CA, Jan. 2019. *J Invest Med* 2019 Jan; 67 (1), 200 (abstr #311)
98. Sharma A, Brooke RJ, Bhatt NS, Li Y, Allewelt HB, Bies JJ, Brondon JE, Gloude NJ, Goeckerman ES, Harris KM, Ho RH, Hudspeth M, Huo JS, Jacobsohn DA, Kasow KA, Katsanis E, Kaviany S, Yiouli P, Ktena YP, Lauhan C, Lopez-Hernandez G, Myers KC, Naik S, Olaya-Vargas A, Onishi T, Ramos KN, Rangarajan HG, Roehrs PA, Sampson ME, Shook DR, Skiles JL, Somers KM, Spiegel C, Symons HJ, Uber A, Triplett BM. Reduced Intensity Vs Myeloablative Conditioning Regimen for Pediatric Therapy-Related Myelodysplastic Syndrome/Acute Myeloid Leukemia. Presented at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR, Houston TX, February 2019. *Biol Blood Marrow Transplant* 2019 25(3),S14-15.
99. Sharma A, Brooke RJ, Bhatt NS, Li Y, Allewelt HB, Bies JJ, Brondon JE, Gloude NJ, Goeckerman ES, Harris KM, Ho RH, Hudspeth M, Huo JS, Jacobsohn DA, Kasow KA, Katsanis E, Kaviany S, Yiouli P, Ktena YP, Lauhan C, Lopez-Hernandez G, Myers KC, Naik S, Olaya-Vargas A, Onishi T, Ramos KN, Rangarajan HG, Roehrs PA, Sampson ME, Shook DR, Skiles JL, Somers KM, Spiegel C, Symons HJ, Uber A, Triplett BM. Reduced Intensity Conditioning for Pediatric Therapy-Related Myelodysplastic Syndrome/Acute Myeloid Leukemia is Associated with Reduced Non-Relapse Mortality but No Improvement in Overall Survival". Presented at the Pediatric Blood and Marrow Transplant Consortium (PBMTTC) Meeting, New Orleans LA, May 2019. *Pediatr Blood Cancer* 2019 June;66(2): #1021
100. Gustafson M, Wheatley-Guy C, Bornschlegl S, Dietz A, Gastineau D, Katsanis E, Simpson R, Johnson B. Physical fitness influences the composition of human T cell populations. Presented at the Society for Immunotherapy of Cancer 34<sup>th</sup> annual meeting, National Harbor, Md. *J Immunother Cancer* 2019 Nov;7(S1): P744
101. Sardar M, Katsanis E, Maher KR. Improved Outcomes of Transplant Associated Thrombotic Microangiopathy with Early Initiation of Eculizumab. Presented at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR, Orlando FL, February 2019 *Biol Blood Marrow Transplant* 2020 26(3),S130
102. Niemiro G, Diak D, Mylabathula P, Baker F, Durazo G, Smith K, Zuniga T, Seckeler M, Katsanis E, Simpson R. Isoproterenol infusion mimics the preferential mobilization of effector lymphocytes in response to steady state exercise in healthy humans. Presented at the International Society for Exercise Immunology, Shanghai China, Nov 2019.
103. Smith K, Agha N, Baker F, Bigley A, Kunz H, Niemiro G, Colombo J, Bond R, Bollard C, Katsanis E, Simpson R. Systemic B1-Adrenergic receptor blockade augments NK-cell mobilization in response to acute exercise in humans. *Med Sci Sports Exerc* 2020 Jul; 52(7S):P16.



104. Niemi G, Coletta A, Brewster A, Bevers T, Agha N, Baker F, Basen-Engquist K, Katsanis E, Gilchrist S, Simpson R. T-cell response to exercise training among women at heightened risk of breast cancer. *Med Sci Sports Exerc* 2020 Jul; 52(7S):P 665.
105. Rangarajan HG, Stanek J, Abdel-Azim H, Modi A, Haight A, McKinney C, McKeone D, Buchbinder D, Katsanis E, Abusin G, Ahmed I, Law J, Jorge Galvez Silva J, Mallhi K, Burroughs L, Shaw PJ, Greiner R, Shenoy S, Pulsipher MA, Abu Arja R. Hematopoietic cell transplantation for congenital dyserythropoietic anemia: a report from the pediatric transplant and cellular therapy consortium (PTCTC). Presented at the American Society of Hematology Meeting, San Diego, CA, December 2020. *Blood* 2020, 136(Supp 1):42-43 #1537
106. Batatinha H, Diak DM, Niemi GM, Mylabathula P, Baker FL, Smith KA, Zúñiga TM, Park Y, LaVoy EC, Katsanis E, Simpson RJ. Human lymphocytes mobilized with exercise extend survival and lower leukemic burden in xenogeneic mice: 1134. *Med Sci Sports Exerc* 2021 53(8S):367
107. Smith KA, Batatinha H, Hoffman EA, Baker FL, Niemi GM, Katsanis E, Simpson RJ. Voluntary wheel running slows tumor progression in a murine lymphoma model: 1132. *Med Sci Sports Exerc* 2021 53(8S):367
108. Baker FL, Mylabathula P, Smith KA, Zúñiga TM, Diak DM, Niemi GM, Markofski MM, Pedlar CR, O'Connor DP, Katsanis E, Simpson RJ. Exercise enhances the anti-leukemia activity of expanded  $\gamma\delta$  T-cells via DNAM-1 upregulation and PVR/Nectin-2 recognition: 1128. *Med Sci Sports Exerc* 2021 53(8S):365-366
109. Zúñiga TM, Baker FL, Smith KA, Gustafson MP, Katsanis E, Simpson RJ. Acute exercise enhances the ex vivo expansion and cytolytic phenotype of cytokine induced killer cells: 1130. *Med Sci Sports Exerc* 2021 53(8S): 366
110. Molina MS, Stokes J, Hoffman EA, Simpson RJ, Katsanis E. Flt3 ligand expressed on the surface of T-cells contributes to effector function. *J Immunol* 2021 206(Supp1)28:05


**GRANT SUPPORT:** Federal Government

**Medical Research Council of Canada Fellowship**

Identification of mechanisms of immunosuppression

7/1/89-6/30/91

Total Direct Costs: \$80,000

PI: Katsanis (100%)

**NIH P01 CA21737**

Autologous bone marrow transplantation for lymphoma: Immunotherapeutic studies

3/1/92-12/31/96

Total Direct Costs: \$520,000

PI: Kersey, PI Project #3: Weisdorf, Co-PI Project #3 Katsanis (15%)

**Department of Defense DAMD17-03-1-0208**

Chronic Myelogenous Leukemia Research Program

Chaperone rich cell lysate (CRCL) vaccine for chronic myelogenous leukemia

5/22/03-5/21/06 relinquished 2/29/04 due to funding of NIH R01 CA104926

Total Direct Costs: \$483,501

PI: Katsanis (25%)

**NIH R21 CA102410**

Multiple chaperone complexes: Natural adjuvants and antigens for dendritic cell-based vaccines

7/1/03-6/30/06

Total Direct Costs: \$300,000

PI: Katsanis (20%)

**NIH R01 CA104926-5**

Chaperone rich cell lysate (CRCL) vaccine for chronic myelogenous leukemia

3/1/04-2/29/09

Total Direct Costs: \$738,000

PI: Katsanis (25%)

**NIH R01 CA104926-9**

Immunotherapy for chronic myelogenous leukemia

7/1/09-4/30/15

Total Direct Costs: \$900,935

PI: Katsanis (25%)

**NIH R01 NR010889**

Childhood leukemia: Oxidative stress, cognitive changes &amp; academic outcomes

5/15/09-3/31/15

Total Direct Costs: \$2,089,367

PI: Moore, Co-investigator: Katsanis (5%)

**NASA HRP Omnibus**

 The impact of simulated microgravity on the anti-tumor properties of human NK-cells and  $\gamma\delta$ -T cells in vivo: IL-2 and zoledronic acid therapy as a potential countermeasure

05/21/19-05/20/20

Total Direct Costs: \$150,000

PI (Simpson PI), Co-PI: Katsanis (5%)





**NASA Omnibus 2 19-19OMNI2 20021**

Exercise training as countermeasure for anti-tumor immune dysregulation due to isolation and confinement stress

12/31/20-12/31/21

Total Direct Costs: \$150,000

PI (Simpson PI), Co-PI: Katsanis (5%)

**GRANT SUPPORT:** [State Government](#)

---

**Arizona Disease Control Research Commission**

Improvement of anticancer immune responses generated by chaperone protein associated tumor peptides

7/1/99-6/30/01

Total Direct Costs: \$392,791

PI: Katsanis

**Arizona Disease Control Research Commission**

Development of antisense oligonucleotides as chemotherapeutic agents for intratumoral administration

7/1/99-6/30/01

Total Direct Costs: \$383,032

PI: Whitesell, Co-Investigator: Katsanis

**Arizona Disease Control Research Commission**

Heat shock proteins as targets for drug discovery

7/1/01-6/30/03

Total Direct Costs: \$367,236

PI: Whitesell, Co-Investigator: Katsanis

**Arizona Disease Control Research Commission (#8-028)**

Chaperone rich cell lysate vaccine for ovarian cancer

7/1/03-6/30/06

Total Direct Costs: \$273,828

PI: Katsanis



**GRANT SUPPORT:** National Private Foundations

---

**Canadian Cancer Society Fellowship, Gordon E. Richard Award**

Treatment of pediatric cancers

7/1/86-6/30/87

Total Direct Costs: \$34,440

PI: Katsanis

**Ronald McDonald Children's Charities**

Use of immunochemotherapeutic agents against murine neuroblastoma

10/1/91-9/30/92

Total Direct Costs: \$17,350

PI: Katsanis

**American Cancer Society Clinical Oncology Career Development Award 93-30,**

Generation of a specific immune response against neuroblastoma

7/1/93-6/30/96

Total Direct Costs: \$90,000

PI: Katsanis (50%)

**Cancer Research Foundation of America**

Development of anti-tumor vaccines for neuroblastoma

10/1/94-9/30/95

Total Direct Costs: \$30,000

PI: Katsanis

**Concern Foundation for Cancer Research**

Induction of antitumor immunity against neuroblastoma by gene modified APCs

1/1/96-6/30/98

Total Direct Costs: \$35,120

PI: Katsanis

**American Cancer Society IM-785**

Augmentation of anti-tumor T cell responses by GM-CSF activated antigen presenting cells

1/1/96-12/31/99

Total Direct Costs: \$255,200

PI: Katsanis (25%)

**W.M. Keck Foundation**

Development of tumor-specific immunity in transgenic mice

7/1/98-6/30/01

Total Direct Costs: \$165,000

PI of project #4: Katsanis

**Leukemia and Lymphoma Society, Translational Research Grant**

Analysis of T cell response to the bcr/abl gene product

12/31/98-12/30/02

Total Direct Costs: \$300,000

PI: Katsanis (20%)



**Hyundai Hope Research Grant**

Combinatory immunotherapy for acute leukemia following hematopoietic stem cell transplantation  
12/1/11-11/30/13

Total Direct Costs: \$100,000

PI: Katsanis

**Hyundai Scholar Senior Researcher Award**

Post-transplant bendamustine, a novel approach to T replete haploidentical BMT  
10/1/15-12/31/17

Total Direct Costs: \$250,000

PI: Katsanis

**Leukemia and Lymphoma Society Translational Research Program (TRP) #6512-17**

A Phase I/II Study of Haploidentical Bone Marrow Transplantation with Post-Transplant  
Cyclophosphamide and/or Bendamustine

10/1/16-6/30/20

Total Direct Costs: \$540,054

PI: Katsanis

**Hyundai Hope Scholar Grant**

A continuous cancer vaccine platform employing a cell based implantable device  
12/31/20-12/31/22

Total Direct Costs: \$300,000

PI: Katsanis

**Hyundai Hope on Wheels Impact Grant**

Immune responses to SARS CoV-2 in pediatric cancer patients  
12/31/21-12/31/22

Total Direct Costs: \$100,000

MPI: Simpson-Katsanis



**GRANT SUPPORT:** Local Private Foundations

---

**People Acting Now Discovering Answers (PANDA)**

Children's cancer immunology program  
7/1/10-6/30/12  
Total Direct Costs: \$200,000  
PI: Katsanis

**iMAGine**

Leukemia research  
7/1/10-6/30/13  
Total Direct Costs: \$30,000  
PI: Katsanis

**Angel Charity for Children**

Translating pediatric cancer research to clinical trials  
5/1/14-4/30/16  
Total Direct Costs: \$480,000  
PI: Katsanis

**People Acting Now Discovering Answers (PANDA)**

Children's cancer immunology program  
7/1/15-6/30/20  
Total Direct Costs: \$400,000  
PI: Katsanis

**Courtney's Courage**

Novel immunotherapies for pediatric cancer  
1/1/00-12/31/21  
Total Direct Costs: \$630,000  
PI: Katsanis



**GRANT SUPPORT:** Institutional

---

**University of Arizona Cancer Center (Clinical Research Oversight Council)**

A Phase I/II Study of Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide and/or Bendamustine  
7/1/16-6/30/18  
Total Direct Costs: \$80,000  
PI: Katsanis

**Improving Health (TRIF)/BIO5 Institute Pilot Grant Program**

Targeting CD47 for checkpoint cancer immunotherapy  
7/1/16-6/30/17  
Total Direct Costs: \$70,000  
PIs: Montfort & Katsanis

**University of Arizona Cancer Center (Clinical Research Oversight Council)**

Targeting the  $\beta$ 2-adrenergic receptor to engineer superior peripheral blood stem cell grafts  
7/1/19-6/30/21  
Total Direct Costs: \$59,900  
PIs: Simpson & Katsanis

**CALS COVID-19 Pilot Project Funding**

Personalized cell therapies to combat COVID-19  
5/1/20-4/30/21  
Total Direct Costs: \$30,000  
PI: Simpson  
CI: Katsanis



**GRANT SUPPORT: Primary Mentor**

---

**Leukemia and Lymphoma Society Fellow Award**

Modulation of regulatory T cell suppressive activity by chaperone rich cell lysate

7/1/06-6/28/09

Total Direct Costs: \$141,000

N. Larmonier

**NIH K23 CA107450**

Hsp90 as a target for the treatment of childhood cancer

9/1/06-8/31/11

Total Direct Costs: \$552,500

R. Bagatell

**America Cancer Society, Mentored Research Scholars Grant**

A multiepitope heat shock protein-based tumor vaccine against HER-2 cancers

1/1/08-12/31/12

Total Direct Costs: \$585,000

S. Andreansky

**Alex's Lemonade Stand Foundation for Childhood Cancer Young Investigator Award**

Reciprocal interactions between tumor killer DC and tumor-induced Treg

7/1/08-6/30/10

Total Direct Costs: \$80,000

N. Larmonier

**NIH K08 AR054323**

Characterization of pathogenic Th17 responses in collagen induced arthritis

7/1/09-6/30/14

Total Direct Costs: \$587,500

S. Sarkar

**Hyundai Scholar Grant**

Assessment of pain during IT chemotherapy

9/1/11-8/30/13

Total Direct Costs: \$50,000

P. Gupta

**NIH Lymphoma SPORE**

Career Development Program in Lymphoma Research

Investigating novel prognostic markers and therapeutic targets for lymphoma

7/1/13-6/30/13

Total Direct Costs: \$25,000

Y. Zeng

**Hyundai Scholar Grant**

Experimental reduced intensity haploidentical hematopoietic stem cell transplant (HSCT) for pediatric solid tumors

1/11/13-10/31/14

Total Direct Costs: \$75,000

L. Kopp



**Hyundai Scholar Young Investigator Award**

Exploring Pak2 regulation of MDSC associated with GvHD and GvL

1/1/16-12/30/17

Total Direct Costs: \$150,000

Y. Zeng



## Investigator Initiated Clinical Trials

---

A Phase I/II Study of Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide and/or Bendamustine  
12/1/16- open  
ClinicalTrials.gov Identifier: NCT02996773  
PI: Katsanis

## PATENTS

---

Methods of recovering chaperone proteins and complexes thereof  
Filing date: March 5, 2002,  
Publication date: April 5, 2005  
Publication number: US 6875849-B2

Vaccine compositions and methods  
Filing date: May 5, 2009,  
Publication date: May 24, 2012  
Publication number: US 20120128656-A1

Obtaining stem cells from a donor used in composition such as pharmaceutical composition and kit for treating leukemia, hematological malignancy or immune system disorder, involves administering stem cell mobilization agent.  
Filing date: Feb 13, 2019,  
Publication date: August 20, 2020  
Publication number: WO2020167948-A1





## MENTORING ACTIVITIES: (University of Arizona)

---

### Junior Faculty Mentor

Nicolas Larmonier, Ph.D., Assistant Professor, Pediatrics, 7/06-6/09, LLS Fellow  
 Rochelle Bagatell, M.D., Associate Professor, Pediatrics, 9/06-8/11, NIH K23 award  
 Samita Andreansky, Ph.D., Assistant Professor, Pediatrics, 1/08-12/12, ACS Mentored Research Scholar  
 Sujata Sarkar, M.D., Assistant Professor, Medicine 7/09-6/14, NIH K08 award  
 Yi Zeng, M.D., Ph.D., Assistant Professor, Pediatrics, 9/12-6/17, Hyundai Scholar Young Investigator

### Faculty Fellow Mentoring Program

G. Alexander Hishaw, M.D., 7/16-6/17, Assistant Professor of Neurology & Psychiatry

### Junior Faculty Research Committees

Nicolas Larmonier, Ph.D., Habilitation à Diriger des Recherches, Université de Bourgogne, 2008

### Postgraduate Level Mentor

Adnan Sarcevic, M.D., M.S. 4/97-10/97 ⇒ Adjunct Assistant Professor, Albert Einstein COM  
 Lin He, M.D., M.S. 7/97-12/99 ⇒ Post-Doc, Northwestern University  
 Michael Graner, Ph.D. 8/97-6/04 ⇒ Associate Professor, University of Colorado  
 Yi Zeng, M.D., Ph.D. 8/03-5/06 ⇒ Associate Professor, University of Arizona  
 Nicolas Larmonier, Ph.D. 8/04-12/06 ⇒ Professor, University of Bordeaux  
 Nona Janikashvili, Ph.D. 1/07-3/10 ⇒ Associate Professor, Tbilisi State Medical University  
 Gang Li, Ph.D., 3/07-8/08 ⇒ School of Dentistry, University of Minnesota  
 Raquel Bravo, M.D., 7/09-6/11 ⇒ School of Public Health, University of Arizona  
 Collin J. LaCasse, Ph.D., 5/11-12/12 ⇒ Medical School, University of Arizona  
 Shivali Justa, Ph.D., 7/14-6/16  
 Rita-Marie McFadden, Ph.D., 8/14-1/15 ⇒ Post-Doc, University of Kansas  
 Sofie de Prins, Ph.D., 1/15-10/15 ⇒ Janssen Pharmaceutical  
 Pricila Moly, Ph.D., 10/16-6/17 ⇒ Post-Doc, University of Arizona  
 Vanessa Garrido, Ph.D., 12/16-6/17 ⇒ Post-Doc, University of Arizona  
 Jelena Eremija, M.D., 2/16 -6/18 ⇒ Pediatric Resident, University of Arizona  
 Grace Niemiro, Ph.D., 7/18-3/21 ⇒ Senior Scientist R&D Abbott Nutrition  
 Forest L. Baker, Ph.D., 10/20-  
 Kristy Gilman, Ph.D., 5/21-



### Graduate Level Mentor

Hanping Feng, Ph.D., Immunology, 2/99-7/02 ⇒ Associate Professor, University of Maryland  
 Yi Zeng, M.D., Ph.D., Immunology, 9/99-8/03 ⇒ Associate Professor, University of Arizona  
 Xinchun Chen, M.D., Ph.D. Immunology, 8/02 – 11/06 ⇒ Professor, Shenzhen -Hong Kong Institute  
 Kerri Kislin, Ph.D., Cancer Biology, 3/03-9/06 ⇒ Translational Genomics Research Institute  
 Gang Li, Ph.D., Immunology, 8/02-3/07 ⇒ School of Dentistry, University of Minnesota  
 Jessica Cantrell, Ph.D., Cancer Biology, 7/05-5/09 ⇒ U. of Colorado, C. of Veterinary Medicine  
 Collin J. LaCasse, Ph.D., Immunobiology, 12/06-5/11 ⇒ Medical School, University of Arizona  
 Tamara Lundeen, M.S., Immunobiology, 8/08 – 8/09 withdrew ⇒ Medical School, U Arizona  
 Sara Bustamante, Ph.D., Cancer Biology, 4/08-5/11 ⇒ Post-Doc, University of Arizona  
 Neale Hanke, Ph.D., Cancer Biology 3/10-12/12 ⇒ Post-Doc, University of Arizona  
 Alexis Bucknam, Immunobiology 2/11-6/12 withdrew ⇒ School Teacher  
 Darya Alizadeh, Ph.D., Cancer Biology 2/11-12/14 ⇒ Post-Doc, City of Hope Cancer Center  
 Martin Asimis, M.S., Molecular and Cell Biology 5/12-5/14 ⇒ Ventana Medical Systems, Inc.  
 Megan Stanley-Molina, Ph.D., Immunobiology, 4/17-5/21 ⇒ Post-Doc University of Washington  
 Helena Batatinha, Ph.D., Cell and Developmental Biology (U. of Sao Paul exchange), 9/19-12/20  
 Andres Diaz M.D.-Ph.D. candidate 3/22-

### Graduate Level Dissertation Committees

John Richards, Ph.D., Immunology, 1998-2002  
 James Kobie, Ph.D., Immunology, 1999-2003  
 Tong Zhang, Ph.D., Immunology, 1999-2003  
 Vivian Mack, M.S., Immunology, 1999-2004  
 Lalitha Ramanathapuram, Ph.D., Immunology 2002-2006  
 Naihsuan Guy, M.S., Immunobiology, 2005-2006  
 Matthew Rausch, Ph.D., Immunobiology, 2005-2009  
 Maria Ordaz, M.S., Immunobiology, 2006-2009  
 Lora Grainger, Ph.D., Immunobiology, 2006-2010  
 Claire Larmonier, Ph.D., Immunobiology, 2007-2010  
 Tiffany Zúñiga, Ph.D., Nutritional Sciences, 2019-  
 Douglass Diak, Ph.D., Health and Human Performance (University of Houston) 2019-20  
 Preteesh Leo Mylabathula, Ph.D., Health and Human Performance (University of Houston) 2019-20  
 Forest L. Baker, Ph.D., Health and Human Performance (University of Houston) 2019-20  
 Anngela Adams, MD-Ph.D. Basic Medical Sciences 2021-  
 Danyelle Paine, Ph.D., Clinical and translational Sciences 2021-  
 Lisa Olsen, M.S., Genetic Counseling 2021-

### Graduate Level (laboratory Rotations)

Suzanne Stratton, Cancer Biology 9/97-12/97  
 Manolis Demetriou, Cancer Biology 9/99-12/99  
 Elizabeth Tyszka, Cancer Biology 8/00-12/00  
 Michael DeNiro, Cancer Biology 5/02-7/02  
 Maria Ordaz, Immunobiology 4/05-9/05  
 Mark Teng, Cancer Biology 1/08-4/08  
 Rajalakshmy Ramalingam, Immunobiology 4/08-6/08  
 Martin Demant, M.D., 7/15-9/15  
 Alexander Alvarez, MD-PhD student, 6/16-7/16  
 Megan Stanley-Molina, Immunobiology, 10/16-12/16



Stephanie Flatau, Cancer Biology, 1/16-3/16  
Sara Djurich, Physiology 10/18-11/18  
Allison Moreno, Cancer Biology, 1/19-2/19  
Aisha Al-Khinji, Clinical Translational Sciences, 2/19-3/19  
Anutr Sivakoses, Cancer Biology, 10/21-1/22

#### **Undergraduate Level Mentor**

Davis Romney, 11/97-5/98, ⇨ Medical School, University of Virginia  
Amber Kyle, 5/99-12/99, ⇨ Medical School, University of Michigan  
Nicole Davis, 5/98-12/99, ⇨ School of Public Health, Drexel University  
Susan Hoy, 11/98-12/00, ⇨ Graduate School, University of Colorado  
Amy Raymond, 1/99-6/00, ⇨ Graduate School, UC San Diego  
Kamalesh Ramaiya, 5/99-5/01, ⇨ Medical School, University of Arizona  
Hector Sandoval, 6/99-5/00, ⇨ Graduate School, Baylor University  
Anna Likhacheva, 5/00-5/03, ⇨ Medical School, University of Arizona  
Jared Brandenberger, 6/00-5/02, ⇨ Medical School, University of Arizona  
Jane Davis, 5/02-5/04, ⇨ Medical School, University of Arizona  
Sylvia Thompson, 5/03-4/05, ⇨ Medical School, University of Arizona  
Xuemei Cai, 2/03-7/05, ⇨ Medical School, Harvard University  
M. Angela Romanoski, 5/03-7/05, ⇨ Medical School, University of Arizona  
Marjan Sepassi, 3/04-8/07, ⇨ School of Pharmacy, University of Arizona  
Elaine Situ, 8/06-5/09 ⇨ Medical School, University of Arizona  
Amanda Herrell, 1/08-5/10 ⇨ US Peace Corps  
Leila Amini, 9/10-6/11 ⇨ Medical School, University of California Irvine  
Jessica Stokes, 1/12-12/13 ⇨ Research Specialist Sr. (Katsanis Lab), University of Arizona  
Evangelia Assimacopoulos 9/12-5/14 ⇨ Medical School, University of Iowa  
Emily Ann Galoway 8/15-2/16  
Farmaan Judge 8/16-12/16  
Anne Cambrelin 8/16-5/18  
Cecilia Machado 9/18-5/19  
Nicole Kummet 5/19-4/21 ⇨ Medical School, University of Arizona  
Andrew Matiatos 10/20-  
Jenna Wise 1/21-

#### **Minority Health Disparities Summer Research Program**

Irene Adu-Gyamfi, 6/06-8/06

#### **Minority Research Training Program**

Bradley Bowman, 6/09-8/09

#### **Medical Student Research Program**

Jason Wright, 5/08-7/10  
Elaine Situ, 5/09-7/10  
Ellie Hutchison, 5/13-6/14  
Jaime Elizabeth Faulkner, 5/17-6/18  
Kacy Gilbert-Gard, 5/18-8/18



Andres F. Diaz, 5/21-8/21

**Latin American Summer Research Program**

Maria Fernanda Acosta Sanchez Aldana, 6/12-8/12

**Arizona's Science, Engineering, and Math Scholars (ASEMS) program**

Ingrid Peterson 10/14-12/14

**NIH Undergraduate Student Research Program**

Cecilia Machado, 6/16-8/16 & 6/17-8/17, 6/18-8/18

**NIH High School Student Research Program**

Luis Luy, 6/16-7/16 & 6/17-7/17

Sophia Garcia, 6/18-7/18

Daniella Diaz-Jusaino, 6/20-7/20

Julian Grijalva, 6/20-7/20

**Steps 2 STEM High School Research Internship Program**

Angel Roque, 6/19-7/19

**Pediatric Resident Clinical Advisor**

Alejandro de la Torre, M.D., 7/04-6/07

Nathan Price, M.D., 7-07-6/08

Kiran Kulkarni, M.D., 7-08-6/11

**Hematology-Oncology Medical Student Interest Group, Advisor**

2020-



**TEACHING ACTIVITIES: (2000-present)**

---

**Graduate School Courses**

Clinical Cancer Biology CBIO 561, **Course Director, 2008-2013**

Clinical Cancer Biology CBIO 561

- Neuroblastoma, 2008
- Pediatric Leukemia, 2009
- Hematopoietic cell transplantation, 2011
- Hematopoietic cell transplantation, 2013
- Hematopoietic cell transplantation, 2015
- Hematopoietic cell transplantation, 2017

Cancer Therapeutics CBIO 555,

- Cancer Immunotherapy, 2009
- Advances in hematopoietic cell therapies and transplantation, 2019
- Immunotherapies for hematologic malignancies, 2021

Cancer Immunology and Immunotherapy CBIO 565

- Cytokines & adoptive cell transfer, 2010
- Bone marrow transplantation, 2010
- Cancer vaccines, 2010
- Biology of Hematopoietic cell transplantation, 2013

**Medical School Courses**

Medical Microbiology/Immunology 801/501 (Facilitator, Clinical correlates)

- Lymphoma, 2000
- Autoimmunity, 2000
- Transplantation, 2000
- Transplantation, 2001

Dean's Rounds (Facilitator)

- Cultural competency and the cross-cultural interview, 2004

Cancer Block (AZ Med)

- Pediatric Leukemias, 2008
- Pediatric Leukemias, 2009
- Anemia, 2009
- Acute Lymphoblastic Leukemia CBI Case Conference, 2009

Advance Topics Block (AZ Med)

- Anemia, 2010
- Acute Leukemia, 2010
- Acute Lymphoblastic Leukemia CBI Case Conference, 2010



### Resident Teaching Conferences

Pediatric stem cell transplantation: an overview, 2001  
Cancer chemotherapy, 2001  
Supportive care for the pediatric oncology patient, 2001  
Blood transfusions, 2002  
Oncologic emergencies, 2002  
Childhood leukemias, 2002  
Diagnostic approach to the child with anemia, 2003  
Acute lymphoblastic leukemia, 2004  
Bleeding disorders in children, 2005  
Childhood leukemias, 2006  
Pediatric lymphomas, 2006  
Supportive care for children with cancer, 2007  
Childhood leukemias, 2008  
Thrombocytopenia, 2009  
BMT emergencies, 2010  
Bone marrow failure, 2010  
Pediatric stem cell transplant overview, 2011  
Management of the BMT patient, 2012  
Overview of hematopoietic stem cell transplantation, 2013  
Management of the BMT patient, 2014  
Pediatric BMT, 2015  
Complications of hematopoietic cell transplantation, 2018  
Hematopoietic cell therapy and transplantation, 2021

### Nursing Teaching Conferences

Infections following stem cell transplantation, 2000  
Acute lymphoblastic leukemia, 2006  
Tumor lysis syndrome, 2006  
Overview of stem cell transplantation, 2010  
Beware of Myths Taught - Be More Theoretical, 2011  
What oncology nurses always wanted to know about hematology but were afraid to ask, 2011  
Fundamentals of hematopoietic cell transplantation, 2014  
Infections post- hematopoietic cell transplantation, 2014  
Graft versus host disease and immune reconstitution, 2014  
Hematopoietic cell transplantation for non-malignant disorders, 2014  
Overview of hematopoietic stem cell transplantation, 2014  
Management of BMT patients in ICU, 2014  
Hematopoietic cell transplantation: Background and history, 2015  
Fundamental principles of hematopoietic cell transplantation, 2015  
Conditioning regimens and stem cell infusions, 2015  
Infections post- hematopoietic cell transplantation, 2015  
Graft versus host disease and immune reconstitution, 2015  
Hematopoietic cell transplantation for non-malignant disorders, 2015  
Fundamental principles of hematopoietic cell transplantation, 2017  
Conditioning regimens 2017  
Infections post- hematopoietic cell transplantation, 2017  
Graft versus host disease and immune reconstitution, 2017  
Hematopoietic cell transplantation for non-malignant disorders, 2017



Fundamental principles of hematopoietic cell transplantation, 2018  
Conditioning regimens 2018  
Immune reconstitution, 2018  
Hematopoietic cell transplantation for non-malignant disorders, 2018  
Haploidentical bone marrow transplantation, 2018  
Evolution of hematopoietic cell transplantation, 2018  
The University of Arizona Cancer Center HCCT program, 2018  
History of BMT, 2019  
Diseases treated by HCT, the why and how, 2019  
Haploidentical bone marrow transplantation, 2019  
Hematopoietic cell transplantation Background, History and Fundamental Principles, 2021  
Hematopoietic cell transplantation for Non-Malignant Disorders, 2021  
Conditioning Regimens, 2021  
Infections following Hematopoietic cell transplantation, 2021  
Management of Graft failure, 2021  
Treatment of acute and chronic GvHD, 2021  
Immune Reconstitution, 2021

### **Clinical Teaching**

Medical Student Attending, General Pediatrics (3 wk/yr), 1997- 2009  
Pediatric Residents and Medical Students: Inpatient, and electives outpatient, 1997-present



**INTRAMURAL PRESENTATIONS: (2000-present)**

---

- Pediatric Research Conference, Auto-focused vaccine against cancer, 2001
- Pediatric Grand Rounds, The top ten Hem/Onc list for the pediatrician, 2002
- 4th Annual Immunobiology of Cancer Workshop, Tumor-derived multiple chaperone complexes are effective therapeutic vaccines, 2002
- University of Arizona Cancer Center Retreat, Multiple chaperone complexes: The new wave of anti-cancer vaccines, 2002
- Pediatrics Club Meeting, University of Arizona Medical School, Introduction to Pediatric Cancer, 2003
- Women's Cancers Scientific Retreat, Ovarian tumor-derived chaperone-rich cell lysates elicit T cell responses in vitro, 2005
- Obstetrics and Gynecology Grand Rounds, CRCL: An effective autologous vaccine against gynecologic malignancies, 2005
- Pediatric Research Conference, CRCL Vaccine: Closing the circle on cancer, 2006
- Ovarian Cancer Forum, Ovarian cancer vaccine: fact or fiction, 2006
- Pediatric Grand Rounds, The blood's response to pediatric diseases, 2006
- Frontiers in Medical Research Seminar, Heat shock proteins as anticancer vaccines, 2006
- Frontiers in Immunobiology and Immunopathogenesis, Chaperone rich cell lysate: Antigen, Adjuvant, Activator, 2006
- Conversations with Colleagues, Finding your scholarship, College of Medicine, 2008
- Clinical Updates in Oncology Symposium, University of Arizona Cancer Center, Solid progress against pediatric liquid tumors, 2009
- Frontiers in Medical Research Seminar, Tumor Immunology, 2009
- Pediatric Grand Rounds, Acute Myelogenous Leukemia; chemotherapy and beyond, 2010
- Medical Oncology Grand Rounds, University of Arizona Cancer Center, Universal cancer vaccine: both autologous and allogeneic, 2011
- College of Medicine Medical Student Hematology/Oncology Club, Choosing a career in pediatric oncology, 2011
- Emergency Department Ask the Expert Series, Pediatric hematology/oncology emergencies, 2012
- Blood and Marrow Transplant Conference, University of Arizona Cancer Center, Phase I immunotherapy trial for refractory leukemia, 2012
- Minority Access to Research Careers program, The MD-PhD pathway, 2012
- Blood and Marrow Transplant Conference, University of Arizona Cancer Center, The state of our BMT program, 2012
- University of Arizona Cancer Center Collaborative Grand Rounds, Exploiting the qualities of chemotherapeutic agents to entice oncologists to reconsider immune therapies, 2013
- Pediatric Tumor Board, Highlights from the ASBMT/CIBMTR conference, 2013





Blood and Marrow Transplant Conference, University of Arizona Cancer Center, Haploidentical stem cell transplantation, 2013

FACT Inspection, The UAMC BMT program, 2013

Medical Student Hem-Onc Interest Group, BMT 2014

Medical Oncology Grand Rounds, Our BMT program report card, 2014

Lymphoma Monthly Conference, Haploidentical BMT for Lymphoma, 2014

Pediatric Grand Rounds, Hematopoietic cell transplantation: where have we been and where are we going, 2015

Medical Oncology Grand Rounds, BMT from SOS to OS, 2015

UACC's NCI site visit, Inclusion of Children in Clinical Trials, 2016

Cancer Immunotherapy and Transplantation Conference, Immune modulation enhancing graft versus leukemia in the setting of haploidentical hematopoietic cell transplantation, 2016

College of Medicine Panel Discussion, Maintaining your scholarship as a clinician, 2016

Cell Therapy & Regenerative Medicine, Keep it in the family: Will unrelated donors become redundant? 2016

Cancer Imaging Program Retreat, Opportunities and Challenges for Imaging in Immunotherapy, 2016

Medical Oncology Grand Rounds, Ben (Bendamustine), haploidentical-BMT and beyond, 2017

Cancer Biology Seminar Series, Exploiting the immunotherapeutic properties of chemotherapy in allogeneic hematopoietic transplantation, 2017

Hematopoietic Cellular Therapy and Transplant Clinical Meeting, Rely on your family's stem cells or seek help from strangers, 2018

Banner Health Board, Our Integrated Pediatric Hematology-Oncology-BMT program, 2019

Radiation Oncology Conference, Advances in Hematopoietic Cell Transplantation, 2019

University of Arizona Cancer Center Collaborative Grand Rounds, Repurposing chemotherapy in hematopoietic cell transplantation to improve immune reconstitution and graft versus tumor effects, 2020

Hematology-Oncology Fellow's Lecture Series, Hematopoietic cell transplantation and immunotherapies, 2020

Hematology-Oncology Student Interest Group Lecture Series, Career opportunities in Pediatric Hematology-Oncology, 2020

MD-PhD Colloquium, Bench to bedside hematopoietic cell transplantation, 2020



## INVITED PRESENTATIONS: (2000-present)

---

The Leukemia and Lymphoma Society, Washington, DC. Analysis of T cell response to the bcr/abl gene product, 2000

Cancer Vaccines Workshop, Tucson, AZ. Dendritic cell-based vaccines, 2000

Immuno-Designed Molecules (IDM) Inc, Paris, France. Stress proteins and anti-tumor responses, 2001

Grand Rounds, Phoenix Children's Hospital, Phoenix, AZ. Biologic therapy of cancer, 2001

American Society for Clinical Laboratory Science, Arizona/Nevada Division Symposium Southern Arizona Veteran's Administration Hospital, Tucson, AZ. New immunobiologic approaches for cancer, 2002

Earle A. Chiles Research Institute, Portland, OR. Tumor derived chaperone rich cell lysates: Effective adjuvants and antigens for cancer, Immunotherapy, 2003

Grand Rounds, Phoenix Children's Hospital, Phoenix, AZ. The hematologic response to systemic illness in children, 2005

The Biodesign Institute, Arizona State University, Tempe, AZ. CRCL Vaccine: Closing the Circle on Cancer, 2006

Immunovative Therapies, Scientific Advisory Board Meeting, Carlsbad, CA. Chaperone-rich cell lysate; pre-clinical data, 2012

Immunovative Therapies, Scientific Advisory Board Meeting, Carlsbad, CA. Activated Th1 cells; pre-clinical studies, 2012

BC Children's Hospital, Vancouver, Canada. Immunotherapy and Chemotherapy: Unreasonable partners in a working relationship, 2014

Ventana Research Forum, Ventana Medical Systems, Oro Valley, AZ. The emerging application of haploidentical bone marrow transplantation, 2015

University of Arizona Cancer Center and Mayo Clinic Hematologic Malignancies Symposium, Tucson, AZ. Novel approaches in haploidentical hematopoietic transplantation, 2015

Cell Therapy & Regenerative Medicine Symposium, Tucson, AZ. Can graft versus tumor be safely augmented in haploidentical hematopoietic cell transplantation? 2016

Universite de Bordeaux, Bordeaux, France. Should post-transplant cyclophosphamide be the standard of care in haploidentical bone marrow transplantation? 2016

Cardon Children's Medical Center, Mesa AZ. The Banner University of Arizona Blood and Marrow Transplant Program: Progress and Challenges. 2016

Phoenix Children's Hospital, Phoenix, AZ. Haploidentical bone marrow transplantation with post-transplant bendamustine. 2018

Cancers, Immunotherapies and Microbiology. Cancer/VIMID Joint Meeting of Arizona WellBeing Commons, Scottsdale, AZ. Exploiting the immunotherapeutic properties of bendamustine in haploidentical bone marrow transplantation and beyond. 2018

The Leukemia and Lymphoma Society TRP & RTFCCR Progress Meeting, Philadelphia, PA. A Phase I/II Study of Haploidentical BMT with Post-Transplant Cyclophosphamide and/or Bendamustine. 2018

Canvendish Phoenix Biohealth Impact Forum, Phoenix, AZ. Panel Discussion: New directions in cancer care. 2019



Banner Children's Monthly Lecture Series, Glendale, AZ. Advances in pediatric oncology and hematopoietic cell transplantation in the era of immunotherapy. 2020

Society for Immunotherapy of Cancer. Advances in Cancer Immunotherapy (Virtual Program): Organizer and Moderator. 2020

Children's Mercy Hospital, Kansas City Missouri. Phase I/Ib trial of Post-Transplant Cyclophosphamide/Bendamustine in Haploidentical-Bone Marrow Transplantation. 2021